

SHIKARI

Biological Drug
Monitoring ELISA Kits

Product Catalog
6th Edition

november
2023

“Shikari® biological drug monitoring ELISA kits can personalize the usage of drugs and enables them to be used effectively and safely.”

Prof. Haluk Ataoglu MD, PhD
CEO

MATRIKS
BIOTEK

20 *years experience*
innovation for health & wellness

Sixth Edition
November 2023

INDEX

MATRIKS BIOTECHNOLOGY®.....	5
RESEARCH & DEVELOPMENT	6
WHY SHIKARI® KITS?.....	7
BIOLOGICAL THERAPY OPTIMIZATION.....	8
IMMUNOGENICITY AGAINST BIOTHERAPEUTIC DRUGS.....	9
Importance of Drug Tolerance	9
Efficacy Considerations.....	9
SHIKARI® ELISA KITS FOR DETECTING ANTI-DRUG ANTIBODIES (ADA)	10
Shikari® Elisa Kits Test Formats	10
Example: Shikari® Q-ATI Total/Free ADA.....	10
BIOSIMILARS: SIMILAR BUT NOT IDENTICAL.....	11
CONTRACT MANUFACTURING ELISA KITS FOR YOUR BIOSIMILAR DRUG (PK&ADA)	11
Why and how to test biological drugs?.....	12
PRODUCTS.....	13
ABATACEPT	14-15
ADALIMUMAB	16-18
AFLIBERCEPT	19-20
ATEZOLIZUMAB	21
AVELUMAB	22
BEVACIZUMAB.....	23-24
CANAKINUMAB	25
CERTOLIZUMAB	26
CETUXIMAB.....	27
DARATUMUMAB	28
DENOSUMAB.....	29
DURVALUMAB.....	30
ECULIZUMAB	31
ETANERCEPT	32
EVOLOCUMAB.....	33
FILGRASTIM	34
GOLIMUMAB.....	35
INFILIXIMAB.....	36-38
INFILIXIMAB BIOSIMILAR.....	39-40
IPILIMUMAB	41
IXEKIZUMAB	42
NATALIZUMAB.....	43
NIVOLUMAB	44
OMALIZUMAB	45
PALIVIZUMAB.....	46
PEMBROLIZUMAB.....	47
PERTUZUMAB.....	48
RAMUCIRUMAB	49
RANIBIZUMAB	50
RISANKIZUMAB.....	51
RITUXIMAB	52-53
SECUKINUMAB	54
TOCILIZUMAB	55
TRASTUZUMAB	56
USTEKINUMAB	57-58
VEDOLIZUMAB	59-60
PRODUCT LIST.....	61-64
FOR ORDER	65
REFERENCES	66-67
PUBLICATIONS	68-77
Journal Articles	68
Posters.....	75
Thesis.....	77
Patents	77



MATRIKS BIOTECHNOLOGY®

Matriks Biotechnology® is a biotechnology company that conducts research on biotechnology, developing products and offering its products at global scale helping people to lead a better life.

Matriks Biotechnology is a medical biotechnology company founded by Prof. Haluk Ataoglu MD, PhD (Microbiology & Immunology) in 2002. He is an academic turned founder and CEO of the company. Company conducts research on life sciences and biotechnology, develops and offers its products at a global scale for helping people to lead a better life. The company is celebrated its 20th anniversary in the year of 2022.

Matriks Biotek® globally is the first company to produce and to commercialize ELISA kits to monitor biological drugs under the brand name of SHIKARI® since 2008 and with its products creating a world market for therapeutic drug monitoring for large molecules.

As indicated by published records in this field, measurement of trough levels of the patients receiving the drug enables us to understand the drug levels are at the optimal dose range or not is critical. If the dose is higher than optimal dose, dosing intervals can be adjusted for longer periods or the dose is reduced to gain optimal dosage. If there is loss of response (LOR) then trough levels will be measured below the effective dose and in this case, dose can be increased and anti-drug antibody (ADA) assay should be used to see if there is ADA that may lead to change to a different available biological drug. Monitoring biological drugs enable the valuable biologics to be used effectively and safely. Proactive biological drug monitoring also has immense importance on cost effectiveness, minimum of 10% in expenditure of biological drugs thus it has a very considerable impact on the economy. Also, offering tests along with the biological drugs may convince social security companies and governments if proper usage and cost effectivity is an issue.

After the pandemic started, the company has done extensive research and developed the most informative "real quantitative" 16 CoronaHunter® ELISA kits which are unique in the market. Kits measures immunoglobulin G, A, M and E values to STRIMER, Spike S1, Spike RBD and Nucleocapsid proteins of Covid-19. Accurate determination of Immunoglobulin G, A, M and E antibody concentrations which are expressed as µg/ml give the correct information that enables sustainable and harmonized results among the tests performed. IgE measuring kits are the only kits in the market to measure specific allergies to covid 19 proteins.

All kits are validated by using panel sera and various other sera obtained from The National Institute for Biological Standards and Control (NIBSC is the world's major producer and distributor of WHO international standards and reference materials). It is the first time The National Institute for Biological Standards and Control panel standard values are measured and expressed as µg/ml "absolute" values providing valuable information for comparisons and enabling harmonization of the results.

Recently by using CoronaHunter® COR-QNS-IGG-SRBD KIT we have measured the WHO international standards and reference materials' "absolute values" of the 5 panel sera (20/268) and the results are given as µg/ml to allow comparison and harmonization of the results between the laboratories. <https://www.linkedin.com/feed/update/urn:li:activity:6885241659429408768/>

Company has 91 different ELISA kits for 36 biological drugs and 16 different ELISA kits for the determination of Covid-19 antibodies in the market with a total of 106 products. These are the highest number and variety of products with highest quality and unique in these respective fields. Also, there are new kits in our pipeline under the SHIKARI® brand that will be launched in the coming days. There are over 160 publications that were written by using SHIKARI® and CoronaHunter® brands ELISA kits.

Matriks Biotek® is one of the rare biotechnology companies in the world positioning itself as an R&D company that allocates half of its revenue to R&D investments by conducting continuous R&D and selling its products directly or with qualified distributor partners with its own brand or through OEM agreements.

Production is conducted with expert scientists in accordance with ISO 13485:2016 quality management system and the company has CE-IVD mark for all their products for Europe.

Our aim at the company is to focus on exporting products worldwide. Company is exporting more than 95% of its production over forty countries some of them namely USA, European Union, China, South Korea, Israel, Saudi Arabia, Japan, Iraq, Norway, Russia, Canada, Taiwan, Ireland, United Kingdom, Australia and New Zealand. The company also has provided its products over thirty pharmaceutical companies that are producing biosimilar drugs. Our company is open to institutional co-operations.



RESEARCH & DEVELOPMENT

Focused on understanding the mechanisms of the various diseases, discovery of new targets for disease treatment and diagnosis, Matriks Biotech® is consistently in the endeavor of adding new products to its pipeline.

Major specific areas of interest for biotherapeutics and novel markers for diseases are as follows:

Covid-19 and Post Covid-19 Era:

Tools for better understanding the response to infections and vaccinations: Protection, inflammation, and immunodeficiency w/specific preference to Covid-19, long and repeating Covid-19 infections. Develop more products for better understanding the immune response to disease and follow up for immune response with respect to inflammatory, autoimmune disorders and immunodeficiency which may occur after infection and even after vaccination.

Biological drug monitoring:

Continue to expand product range and develop more informative kits. Collaborate with clinics, labs, research institutes and CRO's for better understanding of trough levels of the biologics and cost effectiveness studies. Collaborate with pharmaceutical companies which are developing biosimilar or original drugs for PK and immunogenicity work. We are open to custom ELISA production for biosimilar and original drugs.

Develop algorithms to personalize biological drugs to each person to use their drug effectively and safely. Take preventive measures immediately e.g. when anti-drug antibodies develop and/or blood levels of the drug fall under trough levels.

Infectious diseases:

Diagnosis of candida infections,

H2020 Phase1 EU project: A Nanotechnology Based Blood Culture Medium to Detect Invasive Candida in Bloodstream, <https://cordis.europa.eu/project/id/877651>. Phase1 of the EU project has been completed and project will continue with Phase 2.

Our company has developed monoclonal antibodies potentially to diagnose and/or candidate to treat fungal deep seated Candida sp.

Infection, Inflammation and Autoimmunity:

Inflammatory Bowel Disease: Development and validation of novel marker(s) in Crohn's disease to enlighten the etiology, disease activity and distinguish it from Ulcerative Colitis. Our laboratory has various novel modalities to be used to resolve these challenges.

Senescence and inflammation.

Company also focuses on antibody markers for follow up of autism and other mental disorders during treatment.

* Matriks Biotech®, SHIKARI®, KLONART®, CORONAHUNTER® and CANDIDAHUNTER® are registered Trademarks of Matriks Biotechnology Co. Ltd.

MATRIKS
BIOTEK
"trace & catch"



WHY SHIKARI® KITS?


- Each kit's dynamic measurement range optimized for Cmax-Cmin (trough) values of the drugs. Also, researchers can also measure biological levels of the drugs in human, mouse, rat and monkey serum or plasma samples for pharmacokinetic studies.
- More than 160 publications has been made by using SHIKARI® ELISA kits.
- All SHIKARI® ELISA kits are validated in compliance with international standards and easy to publish results.
- Quantitative ELISA kits for anti-drug antibodies (immunogenicity) with confirmation reagent available for 18 different biological drugs. Matriks Biotek® is the first biotechnology company which produced ELISA kits for Remsima® (Infliximab Biosimilar CT-P13). Kits for Remsima® includes quantitative free drug detection kits, qualitative Anti-Remsima® detection kits and total antibody detection kits for Remsima®.
- Total antibody kits have been developed to identify anti-drug antibodies that are bound by drugs in the serum and cannot be determined by free antibody detection kits. Matriks Biotek® developed total antibody detection kits for 3 different drugs: Infliximab (Remicade®, Remsima®) and Adalimumab (Humira®). These TOTAL kits also measure free anti-drug antibodies simultaneously allowing comparisons between total and free anti-drug antibodies giving semi-quantitative results. Kits are unique in the market. Total antibody detection kit development studies for different drugs are ongoing, please inquire.
- Quantitative ADA detection kits include confirmation reagent to eliminate false positives when reporting the results. Unique in the market.
- Inter and intra assay CV to fulfill requirements for FDA & EMEA.
- High recovery rates (%85-115),
- Low sample volumes (10-25 µl) even if you have very small samples such as mouse serum
- All liquid and highly stabilized ready to use reagents.
- Delivery is at room temperature. Cost saver!
- The highest quality material used.
- Microplates NUNC®, Perfect binding of proteins minimum %CV across the entire plate and perfect match with our proprietary blocking buffer almost no background with very long shelf life
- Plastic bottles Nalgene® very durable with perfect surface property
- Glass vials Schott® used for standard containers; vigorously tested. No protein binding clear glass w/ cap when compared to other brands
- SHIKARI® ELISA kits are in 96 well format and you can run as much as 90 samples from each kit.
- Time saver: Short incubation times for biologics testing (70-140 min)
- 1 year expiry date
- Short delivery times
- Project development for custom ELISA kits to measure PK and immunogenicity for your specific biosimilar or original molecule.
- Kits are suitable for biosimilar work. Kits utilize recombinant human proteins ligand binding assay
- No radioactivity
- All Shikari® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.



Matriks Biotek® is now certified for quality management system ISO 13485:2016. All of the SHIKARI® products from Matriks Biotek® are marked with the CE IVD mark according to Council Directive 98 / 79 / EC relating to In Vitro Diagnostic Medical Device Directive.


BIOLOGICAL THERAPY OPTIMIZATION

Algorithm for Therapeutic Drug Monitoring



Keep monitoring drug-levels and antibodies against drug with SHIKARI® ELISA KIT for PRECISE TREATMENT!

For more information please visit;
www.matriksbiotek.com



IMMUNOGENICITY AGAINST BIOTHERAPEUTIC DRUGS

Immunogenicity is well defined but is an undesirable situation in the development of biological drugs and in the treatment process. Immunity to biotherapeutics greatly affects product safety and efficacy. Especially, anti-drug antibodies (ADA) can impact drug exposure by affecting the ability of the drug to reach the intended target, alter the PK profile, and potentially mediate serious adverse effects.

The clinical effects of patient who use biological drugs, immune responses are highly variable, ranging from no effect at all to extremely harmful effects (such as anaphylaxis, cytokine release syndrome, and cross-reactive neutralization of endogenous proteins mediating critical functions) on patient health.

The immunogenic response generally includes both cellular (T cell) and humoral (antibody) arms of the immune response and some factors originating from the patient and the product, are affecting the immunogenicity against biological drugs. Antibodies directed against TP (antidrug antibodies, ADA) may consist of IgM, IgG, IgE, and/or IgA isotypes.


An ADA response can result in a loss of efficacy and/or increase the risk of adverse reactions (e.g., infusion reactions, anaphylaxis, or immune-complex-mediated diseases). In rare cases, the ADA response is directed not only to the administered biotherapeutic but also to its endogenous counterpart protein and may elicit a life-threatening response if the endogenous protein is unique and nonredundant and has a vital life function. In recognition of these possibilities, the regulatory agencies request that a biotherapeutic's immunogenicity be assessed and a determination of its characteristics relative to any induced clinical consequences be done as part of the approval process for biotherapeutics.

Importance of Drug Tolerance

- Immunogenicity assays routinely utilize the therapeutic agent as a cornerstone, typically by immobilization of the drug
 - Specificity of detected anti-drug antibodies is often confirmed by a reduction in binding of the ADA in the presence of excess soluble drug
 - Circulating immune complexes can form when soluble residual drug is present in patient's blood
 - The presence of soluble drug in the patient's serum sample for ADA analysis can inhibit the assay from detecting antidrug antibodies
- Definition of Drug Tolerance**
- Drug tolerance describes the sensitivity of your anti-drug antibody assay in the presence of soluble drug
 - Tolerance is determined by assessing assay sensitivity in the presence of increasing amounts of added soluble drug
- Potential Effect of Antibody Response**
- Safety Considerations**
- Risk for hypersensitivity reactions
 - Potential for immune complex disease

Efficacy Considerations

- Antibodies may bind to drug and alter the pharmacokinetics
- Antibodies may alter the biodistribution of the drug
- Antibodies may bind to (or near) the active site of a drug and inhibit its activity
- Antibodies may bind in a way that interferes with the drug binding to its receptor or ligand



CLINICAL IMMUNOGENICITY

- Risk of Clinical Sequelae
- "Binding" ADA
 - PK-altering ADA
 - Neutralizing ADA
 - Hypersensitivity ADA
 - Cross-Reactive Neutralizing ADA

The severity of Anti Drug Antibody (ADA) impact and its frequency of occurrence have been inversely correlated.

SHIKARI® ELISA KITS FOR DETECTING ANTI-DRUG ANTIBODIES (ADA)

Matriks Biotek® has produced several ADA kits for immunogenicity measurements with different formats. Strategic approach for measurement of drug level and ADA is to take samples just or 1-2 days prior to administering the next drug dose where the the clearance of the drug achieved mostly.

SHIKARI® ELISA KITS TEST FORMATS:

- Screening for free antidrug antibody ELISA kit:

In this test format, the plate is coated with the drug and anti-drug antibodies against this drug are captured by the drug. Same drug labeled with the enzyme and used for monitoring the ADA in the sample.

- Quantitative free antidrug antibody kit with confirmation:

In this test format, the plate is coated with the drug and anti-drug antibodies against this drug are captured by the drug. Same drug labeled with the enzyme and used for monitoring the ADA in the sample. Quantitation is done by standard curve which are composed of decreasing amount of neutralizing monoclonal antibodies giving precise results. After measuring the ADA levels, the samples can be confirmed with a "Confirmation Reagent" discriminating

- Semi quantitative Total/Free ADA free and total antidrug antibody ELISA kit:

Kit enables to measure free and total antidrug antibodies simultaneously within the same kit and same assay protocol. Samples either used directly to measure free ADA and/or used by first acid dissociation then after measured for total ADA. Acid dissociation disrupt circulating immune complexes and enables to detect and measure bound ADA along with free ones. Thus, ADA assay has high drug tolerance giving more information about the occurring ADA and patient status. Kit contains negative, positive and immune-complex standards enabling to control of the assay procedure.

EXAMPLE: SHIKARI® Q-ATI Total/Free ADA

Semi-quantitative SHIKARI® ELISA kits for Total and Free anti-drug antibodies to Infliximab (Remicade®)

Specifications of the test:

- Detects "Free" and "Total" anti-drug antibodies with the same kit simultaneously.
- After dissociation step for total ATI, the kit uses the same assay protocol as free ATI
- Requires only 40 µl of serum/plasma sample
- Total incubation time is as short as 1h 35min.
- Easily adaptable to automation.
- Contains reactive, negative and immune-complex (drug+neutralizing antibody) control
- Lowest detection limit: 156 ngr/ml

Biosimilars: Similar but not identical

Contract manufacturing ELISA kits for your biosimilar drug (PK&ADA)

A biosimilar is highly similar to, but not exactly the same as the existing, FDA-approved biologic, called the “reference” drug. People are familiar with generic versions of brand-name drugs, but biosimilars are not generic drugs. Generic versions of brand-name drugs are exact copies of chemically synthesized medicines. Biosimilars are not-quite-perfect copies of biologics – drugs derived from living cells that are impossible to replicate exactly.

Development of biosimilar proteins will present drug developers with a variety of challenges, both in manufacturing and in the clinic. Immunogenicity will prove to be one of the biggest challenges. Proper design and validation of an assay to detect anti-drug antibodies and accurate interpretation of sample analysis results will prove integral to developing a biosimilar protein.

Taking the above and below-mentioned subjects into account Matriks Biotek® offers to develop custom ELISA kits for your biosimilars or biologics on contract manufacturing basis depending on the molecule provided. Matriks Biotek® also offers test optimizations for drug measurements in formulation buffer and in cell culture medium as well. Our drug measurement (PK) kits utilize drug target ligand (recombinant protein) for detection that makes more suitable for biosimilar drug measurements.

Comparisons for measuring especially ADA and trough levels are made by the tests developed for reference drug not for biosimilar which may differ on the test results. On the contrary, we do not know the results when comparisons were done by the ELISA kit developed for the biosimilar drug, it can present low immunogenicity as well.

The causes of immunogenicity can be chimeric biological drugs (e.g. infliximab), even humanized molecules (e.g. adalimumab) and fully humanized biological drugs (golimumab)—most the cases the residual immunogenicity resides in the CDR regions glycosylation profiles, fermentation, purification, formulation (aggregate formation), administration mode (i.m., i.v. and s.c.), dosing, degradation products and contaminants.

The pharmaceutical formulation strategy is a critical step and needs to be accurate. The knowledge about physical and biological properties of the biological drug orientate the formulation process. Important components of protein formulations are pH, stabilizer, solubilizer, buffer, and tonicity modifier (bulking agent). The typical stability problems observed in protein pharmaceuticals are non-covalent aggregation, covalent aggregation, deamidation, cyclic imide, and cleavages. This process can affect directly the efficacy (e.g. immunogenicity) and safety (e.g. adverse events) of a biological drug.

The potential immunogenicity of a therapeutic protein can be influenced not only by the manufacturing processes mentioned above but also by the type of disease, route of administration and dose. Biosimilar proteins will most likely not be identical to the innovator drug, and because of this, immunogenicity becomes a major concern when developing biosimilar proteins. The potential exists for serious clinical consequences due to anti-drug immune responses with all protein therapeutics. A safe immunogenicity profile of the innovator product does not indicate that the biosimilar protein will be safe.



WHY AND HOW TO TEST BIOLOGICAL DRUGS?

EXAMPLE CASE

Patient: Timothy Richmond

42 years old

Working in an automotive factory for 17 years.

"4 years ago, I visited a gastroenterologist complaining of stomach ache, diarrhea, loss of appetite, loss of weight and fatigue and he asked me to get some tests after the physical examination. I took the tests he asked for. And based on these findings, he diagnosed me with "Crohn Disease" and I started therapy. I took conventional medication that he prescribed for my therapy for 3 years. At first, everything seemed okay. My complaints were gradually relieved. But, for almost a year, the clinical profile of my disease has changed. The developing of fistulas were started. My physician added the TNF blocker to the therapy protocol. I benefited from it for the first 8 months. After months 9 and 10, while I was taking it once every 8 weeks regularly, on the week 5 after month 9, my complaints began to increase. My physician suspected it and asked me to make a blood test to measure the drug level. It was the first time that a physician asked me for such a test. It seems that these things happen when you take drugs. After taking the drug for a while, my body developed an antibody against the drug and blocked its effect. And there are kits to determine that. The physician may modify the therapy depending on the results of this test. And at the laboratory that he referred me to, the tests performed with the said kits revealed that my body develops antibody against the drug. My physician added another drug to the protocol to support my immune system. It has been a month now. I feel very good. And I know where to go and what to ask if I experience any problems."

Physician

"Tim is my patient for 4 years. I diagnosed him with Crohn Disease that is an inflammatory bowel disease. I recommended conventional drugs for his therapy. For the first 3 years that I was following him, there was no problem, but when he came visiting me a year ago, his complaints were increased. I also observed the development of fistulas. The first thing that came to my mind was to add an anti-TNF blocker to the therapy protocol. We started the drug. The therapy was a success for 8 months. However, from months 9 and 10, the complaints of the patient began to increase again. I thought that his body might have developed antibody against the biological drug and asked him to take a test. The only way to find this out was to determine the antibody presence with an ELISA kit. I know a laboratory that I trust very much in these types of cases. I trust them both in terms of personnel and the kits they use. They work with Shikari® ELISA Kits from the beginning. And I never saw them go wrong. I am a physician who believes in the customization of the therapies. It is true that people differ from each other genetically and biologically. And therefore, it is natural for different diseases to have a different course in different people. Why should the therapy be the same then? It should be customized to the individual. I always discuss this in detail with each and every patient that I start to treat. If there are ups and downs during the therapy, i.e. if they do not improve even though they take drugs or they worsen after a while, they inform me. I even have patients that ask for tests with ELISA kit without me recommending it if there is something wrong."

Laboratory official

"We can't say that there are a great number of physicians who refer their patients to our laboratory to test the antibody development against the drugs they use. But, as a matter of fact, this rationalist way is becoming a more frequent method gradually. And the reason is the patients themselves. If the patient knows that there is such a method, he warns his physician. If it is an adept and principle physician, there is no need to do that; but the knowledge and the awareness of the patient here is what determines it. We work with Shikari® ELISA Kits from the beginning. Because the results of the tests performed with these kits comply very well with the clinic of the patient."

** The names mentioned in this story are fictitious and do not reflect real persons.*

PRODUCTS



ABATACEPT SHIKARI®


Q-ABA • S-ATAB • S-ATAB w/confirmation

ABATACEPT (Orencia®) ELISA

Abatacept is a disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease. Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is a selective costimulation modulator - like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This results in the inhibition of autoimmune T-Cell activation that has been implicated in the pathogenesis of rheumatoid arthritis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ABA: Enzyme immunoassay for the quantitative determination of Abatacept (Orencia®) in serum and plasma. This kit has been especially developed for the quantitative determination of Abatacept in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-ABA) Abatacept ELISA



Catalog Number/Code	Q-ABA ABA-FD-ORE
Required Volume (µl)	10
Total Time (min)	105
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	3
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

ABATACEPT SHIKARI®


Q-ABA • S-ATAB • S-ATAB w/confirmation

ABATACEPT (Orencia®) ELISA

SHIKARI® S-ATAB: Enzyme immunoassay for the qualitative determination of specific antibodies to Abatacept (Orencia®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Abatacept in serum and plasma samples.

SHIKARI® S-ATAB w/confirmation: Enzyme immunoassay for the quantitative determination of specific antibodies to Abatacept (Orencia®) in serum and plasma. This kit has been especially developed for the quantitative determination of specific antibodies to Abatacept in serum and plasma samples.

Shikari® (S-ATAB) Anti-Abatacept ELISA w/confirmation



Catalog Number/Code	S-ATAB ABA-QLS-ORE	S-ATAB w/confirmation ABA-QNS-ORE
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	50
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

ADALIMUMAB SHIKARI®

Q-ADA • QS-ADA • S-ATA • S-ATA w/confirmation • S-ATA (Free/Total Ab)

ADALIMUMAB (Humira®) ELISA


Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.


SHIKARI® Q-ADA: Enzyme immunoassay for the quantitative determination of Adalimumab (Humira®) in serum and plasma. This kit has been especially developed for the quantitative determination of adalimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-ADA: Adalimumab ELISA has been especially developed for the specific and quantitative analysis of free adalimumab in serum and plasma samples.

Shikari® (Q-ADA) Adalimumab ELISA



Shikari® (QS-ADA) Adalimumab ELISA



Catalog Number/Code	Q-ADA ADA-FD-HUM	QS-ADA ADA-SPEC-ADA
Required Volume (µl)	20	20
Total Time (min)	70	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	18,75
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

ADALIMUMAB SHIKARI®

Q-ADA • QS-ADA • S-ATA • S-ATA w/confirmation • S-ATA (Free/Total Ab)

ADALIMUMAB (Humira®) ELISA


Demonstration of anti-adalimumab antibodies during treatment with Adalimumab (Humira®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Matriks Biotek® SHIKARI® S-ADA Total/Free ADA ELISA Kit adalimumabspecific antibodies that are bound to adalimumab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Humira®.

SHIKARI® S-ATA: Enzyme immunoassay for the qualitative antibodies to Adalimumab (Humira®) in serum and plasma samples. This kit has been especially developed for the qualitative antibodies to Adalimumab in serum and plasma samples.

SHIKARI® S-ATA w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Adalimumab (Humira®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Adalimumab in serum and plasma samples.

SHIKARI® S-ADA (Free/Total Ab): Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to Adalimumab (Humira®) in serum and plasma.

Shikari® Anti-Adalimumab ELISA




Catalog Number/Code	S-ATA ADA-QLS-HUM	S-ATA w/confirmation ADA-QNS-HUM	S-ATA (Free/Total Ab) ADA-QNFT-HUM
Required Volume (µl)	20	20	40
Total Time (min)	140	140	95
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	+ / -	7,5	250
Spike Recovery (%)	-	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Qualitative	Quantitative	Semi Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

ADALIMUMAB SHIKARI®

Q-ADA • S-ATA • S-ATA w/confirmation • S-ATA (Free/Total Ab)

ADALIMUMAB (Humira®) ELISA

Adalimumab through concentration (TC) measurement



AFLIBERCEPT SHIKARI®


Q-AF • Q-AF HIGH SENSITIVE • S-ATAF • Q-ATAF w/confirmation

AFLIBERCEPT (Eylea®) ELISA

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy. Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Aflibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-AF: Enzyme immunoassay for the quantitative determination of Aflibercept (Eylea®) in serum and plasma. This kit has been especially developed for the quantitative determination of Aflibercept in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-AF) Aflibercept ELISA



Catalog Number/Code	Q-AF AFL-FD-EYL
Required Volume (µl)	5
Total Time (min)	105
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	10
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

AFLIBERCEPT SHIKARI®

Q-AF • Q-AF HIGH SENSITIVE • S-ATAF • S-ATAF w/confirmation


AFLIBERCEPT (Eylea®) ELISA

SHIKARI® Q-AF HIGH SENSITIVE: Enzyme immunoassay for the quantitative determination of Aflibercept (Eylea®) in serum and plasma. This kit has been especially developed for the quantitative determination of Aflibercept in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATAF: Enzyme immunoassay for the quantitative determination of antibodies to of Aflibercept (Eylea®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Aflibercept in serum and plasma samples.

SHIKARI® S-ATAF w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to of Aflibercept (Eylea®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Aflibercept in serum and plasma samples.

Shikari® (Q-AF HIGH SENSITIVE) Aflibercept ELISA



Shikari® (S-ATAF) Anti-Aflibercept ELISA w/confirmation



Catalog Number/Code	Q-AF HIGH SENS. AFL-FD-SENS-EYL	S-ATAF AFL-QLS-EYL	S-ATAF w/confirmation AFL-QNS-EYL
Required Volume (µl)	50	20	50
Total Time (min)	105	140	110
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	1	+ / -	1
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

ATEZOLIZUMAB SHIKARI®

Q-ATE • S-ATAT


ATEZOLIZUMAB (Tecentriq®) ELISA

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers such as advanced or metastatic urothelial carcinoma. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ATE: Enzyme immunoassay for the quantitative determination of Atezolizumab (Tecentriq®) in serum and plasma. This kit has been especially developed for the quantitative determination of Atezolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATAT: Enzyme immunoassay for the qualitative determination of specific antibodies to Atezolizumab (Tecentriq®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Atezolizumab in serum and plasma samples.

Shikari® (Q-ATE) Atezolizumab ELISA



Catalog Number/Code	Q-ATE ATE-FD-TEC	S-ATAT ATE-QLS-TEC
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	5	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

AVELUMAB SHIKARI®

Q-AVE • S-ATAV


AVELUMAB (Bavencio®) ELISA

Avelumab is a monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the immune response resulting in the restoration of immune responses, including anti-tumor immune responses. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-AVE: Enzyme immunoassay for the quantitative determination of free Avelumab (Bavencio®) in serum and plasma. This kit has been especially developed for the quantitative determination of avelumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATAV: Enzyme immunoassay for the qualitative determination of antibodies to Avelumab (Bavencio®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Avelumab in serum and plasma.

Shikari® (Q-AVE) Avelumab ELISA



Catalog Number/Code	Q-AVE AVE-FD-BAV	S-ATAV AVE-QLS-BAV
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	30	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

BEVACIZUMAB SHIKARI®

Q-BEVA • S-ATB • S-ATB w/confirmation


BEVACIZUMAB (Avastin®) ELISA

Bevacizumab is a monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-BEVA: Enzyme immunoassay for the quantitative determination of free Bevacizumab (Avastin®) in serum and plasma. This kit has been especially developed for the quantitative determination of Bevacizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-BEVA) Bevacizumab ELISA



Catalog Number/Code	Q-BEVA BEV-FD-AA
Required Volume (µl)	10
Total Time (min)	70
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	30
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

BEVACIZUMAB SHIKARI®


Q-BEVA • S-ATB • S-ATB w/confirmation

BEVACIZUMAB (Avastin®) ELISA

SHIKARI® S-ATB: Enzyme immunoassay for the qualitative determination of specific antibodies to Bevacizumab (Avastin®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Bevacizumab in serum and plasma samples.

SHIKARI® S-ATB w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Bevacizumab in serum and plasma samples.

Shikari® (S-ATB) Anti-Bevacizumab ELISA w/confirmation



Catalog Number/Code	S-ATB BEV-QLS-AA	S-ATB w/confirmation BEV-QNS-AA
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

CANAKINUMAB SHIKARI®

Q-CAN • S-ATCAN • S-ATCAN w/confirmation

CANAKINUMAB (Ilaris®) ELISA


Canakinumab is a human interleukin-1 β blocker and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1 α or IL-1 receptor antagonist (IL-1ra). Canakinumab is used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-CAN: Enzyme immunoassay for the quantitative determination of Canakinumab (Ilaris®) in serum and plasma. This kit has been especially developed for the quantitative determination of Canakinumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATCAN: Enzyme immunoassay for the qualitative determination of specific antibodies to Canakinumab (Ilaris®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Canakinumab in serum and plasma samples.

SHIKARI® S-ATCAN w/confirmation: Enzyme immunoassay for the quantitative determination of specific antibodies to Canakinumab (Ilaris®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Canakinumab in serum and plasma samples.

Shikari® (Q-CAN) Canakinumab ELISA



Shikari® (S-ATCAN) Anti-Canakinumab ELISA w/confirmation



Catalog Number/Code	Q-CAN CAN-FD-ILA	S-ATCAN CAN-QLS-ILA	S-ATCAN w/confirmation CAN-QNS-ILA
Required Volume (μl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	1	+ / -	31,25
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

CERTOLIZUMAB SHIKARI®

Q-CERT • S-ATCER w/confirmation


CERTOLIZUMAB (Cimzia®) ELISA

Certolizumab pegol is a tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.


SHIKARI® Q-CERT: Enzyme immunoassay for the quantitative determination of Certolizumab (Cimzia®) in serum and plasma. This kit has been especially developed for the quantitative determination of certolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATCER w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Certolizumab (Cimzia®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Certolizumab in serum and plasma samples.

Shikari® (Q-CERT) Certolizumab ELISA



Shikari® (S-ATCER) Anti-Certolizumab ELISA w/confirmation



Catalog Number/Code	Q-CERT CER-FD-CIM	S-ATCER w/confirmation CER-QNS-CIM
Required Volume (µl)	10	5
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	20	5
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

CETUXIMAB SHIKARI®

Q-CET • S-ATC • S-ATC w/confirmation

CETUXIMAB (Erbix®) ELISA


Cetuximab is an endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck. Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-CET: Enzyme immunoassay for the quantitative determination of Cetuximab (Erbix®) in serum and plasma. This kit has been especially developed for the quantitative determination of Cetuximab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATC: Enzyme immunoassay for the qualitative determination of specific antibodies to Cetuximab (Erbix®) in human serum and plasma. This kit has been especially developed for the qualitative determination of Cetuximab in serum and plasma samples.

SHIKARI® S-ATC w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Cetuximab (Erbix®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to cetuximab in serum and plasma samples.

Shikari® (Q-CET) Cetuximab ELISA



Shikari® (S-ATC) Anti-Cetuximab ELISA w/confirmation



Catalog Number/Code	Q-CET CET-FD-ERB	S-ATC CET-QLS-ERB	S-ATC w/confirmation CET-QNS-ERB
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	30	+ / -	30
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

DARATUMUMAB SHIKARI®

Q-DAR • S-ATDAR


DARATUMUMAB (Darzalex®) ELISA

Daratumumab is a CD38-directed cytolytic monoclonal antibody that targets CD38+ multiple myeloma cells. Daratumumab is used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-DAR: Enzyme immunoassay for the quantitative determination of Daratumumab (Darzalex®) in serum and plasma. This kit has been especially developed for the quantitative determination of Daratumumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATDAR: Enzyme immunoassay for the qualitative determination of specific antibodies to Daratumumab (Darzalex®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Daratumumab in serum and plasma samples.

Shikari® (Q-DAR) Daratumumab ELISA



Catalog Number/Code	Q-DAR DAR-FD-DAR	S-ATDAR DAR-QLS-DAR
Required Volume (µl)	5	20
Total Time (min)	100	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

DENOSUMAB SHIKARI®

Q-DEN • S-ATD • S-ATD w/confirmation

DENOSUMAB (Prolia®) ELISA


Denosumab is a RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-DEN: Enzyme immunoassay for the quantitative determination of denosumab (Prolia®) in serum and plasma. This kit has been especially developed for the quantitative determination of denosumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATD: Enzyme immunoassay for the qualitative determination of specific antibodies to denosumab (Prolia®) in human serum and plasma. This kit has been especially developed for the qualitative determination of denosumab in serum and plasma samples.

SHIKARI® S-ATD w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to denosumab (Prolia®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to denosumab in serum and plasma samples.

Shikari® (Q-DEN) Denosumab ELISA



Shikari® (S-ATD) Anti-Denosumab ELISA w/confirmation



Catalog Number/Code	Q-DEN DEN-FD-PRO	S-ATD DEN-QLS-PRO	S-ATD w/confirmation DEN-QNS-PRO
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	18,75
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

DURVALUMAB SHIKARI®

Q-DUR • S-ATDUR


DURVALUMAB (Imfinzi®) ELISA

Durvalumab is an antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Durvalumab blocks programmed death-ligand 1 (PD-L1) to promote normal immune responses that attack tumour cells. . Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-DUR: Enzyme immunoassay for the quantitative determination of Durvalumab (Imfinzi®) in serum and plasma. This kit has been especially developed for the quantitative determination of Durvalumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATDUR: Enzyme immunoassay for the qualitative determination of specific antibodies to Durvalumab (Imfinzi®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Durvalumab in serum and plasma samples.

Shikari® (Q-DUR) Durvalumab ELISA



Catalog Number/Code	Q-DUR DUR-FD-IMF	S-ATDUR DUR-QLS-IMF
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	6	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

ECULIZUMAB SHIKARI®

Q-ECU • S-ATEC • S-ATEC

ECULIZUMAB (Soliris®) ELISA


Eculizumab is a recombinant humanized monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. By the inhibition of this complex, eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce the risk of complement mediated intravascular hemolysis, to prevent complement mediated microangiopathy in atypical hemolytic uremic syndrome and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder (NMOSD).

SHIKARI® Q-ECU: Enzyme immunoassay for the quantitative determination of specific Eculizumab (Soliris®) in serum and plasma. This kit has been especially developed for the quantitative analysis of free eculizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATEC: Enzyme immunoassay for the qualitative determination of specific antibodies to Eculizumab (Soliris®) in serum and plasma. This kit has been especially developed for the qualitative analysis of antibodies to Eculizumab in serum and plasma samples.

SHIKARI® S-ATEC: Enzyme immunoassay for the quantitative determination of specific antibodies to Eculizumab (Soliris®) in serum and plasma. This kit has been especially developed for the quantitative analysis of antibodies to Eculizumab in serum and plasma samples.

Shikari® (Q-ECU) Eculizumab ELISA



Shikari® (S-ATEC) Anti-Eculizumab ELISA w/confirmation



Catalog Number/Code	Q-ECU ECU-FD-SOL	S-ATEC ECU-QLS-SOL	S-ATEC w/confirmation ECU-QNS-SOL
Required Volume (µl)	10	20	5
Total Time (min)	100	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	4,68	+ / -	6,25
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

ETANERCEPT SHIKARI®

Q-ETA S-ATE

ETANERCEPT (Enbrel®) ELISA


Etanercept is a protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis. Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF. Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinases.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ETA: Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®) in serum and plasma. This kit has been especially developed for the quantitative determination of etanercept in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATE: Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®) in serum and plasma. This kit has been especially developed for the qualitative antibodies to Etanercept in serum and plasma samples.

Shikari® (Q-ETA) Etanercept ELISA



Catalog Number/Code	Q-ETA ETA-FD-ENB	S-ATE ETA-QLS-ENB
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	100	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

VOLOCUMAB SHIKARI®

Q-EVO • S-ATEVO


VOLOCUMAB (Repatha®) ELISA

Evolocumab is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. Evolocumab is a human IgG2 monoclonal antibody that targets the proprotein convertase subtilisin/kexin type 9 (PCSK9). Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-EVO: Enzyme immunoassay for the quantitative determination of Evolocumab (Repatha®) in serum and plasma. This kit has been especially developed for the quantitative determination of evolocumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATEVO: Enzyme immunoassay for the qualitative determination of specific antibodies to Evolocumab (Repatha®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Evolocumab in serum and plasma samples.

Shikari® (Q-EVO) Evolocumab ELISA



Catalog Number/Code	Q-EVO EVO-FD-REP	S-ATEVO EVO-QLS-REP
Required Volume (µl)	10	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	6	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

FILGRASTIM SHIKARI®


Q-AFA w/confirmation

FILGRASTIM (Fraven®) ELISA

Filgrastim (Fraven®) was associated to the development of anti-Filgrastim antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Fraven®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Filgrastim antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Filgrastim antibodies.

SHIKARI® Q-AFA: Enzyme immunoassay for the quantitative determination of antibodies to o Filgrastim (Fraven®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Filgrastim in serum and plasma samples.

Shikari® (Q-AFA) Anti-Filgrastim ELISA w/confirmation



Catalog Number/Code	Q-AFA w/confirmation FIL-QNS-FRA
Required Volume (µl)	10
Total Time (min)	140
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	2
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

GOLIMUMAB SHIKARI®

Q-GOL • S-ATG • S-ATG w/confirmation

GOLIMUMAB (Simponi®) ELISA


Golimumab is a TNF α inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Golimumab is a human IgG1k monoclonal antibody derived from immunizing genetically engineered mice with human TNF α . Golimumab binds and inhibits soluble and transmembrane human TNF α . Increased TNF α is associated with chronic inflammation.

SHIKARI® Q-GOL: Enzyme immunoassay for the quantitative determination of Golimumab (Simponi®) in serum and plasma. This kit has been especially developed for the quantitative determination of golimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATG: Enzyme immunoassay for the quantitative determination of antibodies to Golimumab (Simponi®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Golimumab in serum and plasma samples.

SHIKARI® S-ATG w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to o Golimumab (Simponi®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Golimumab in serum and plasma samples.

Shikari® (Q-GOL) Golimumab ELISA



Shikari® (S-ATG) Anti-Golimumab ELISA w/confirmation



Catalog Number/Code	Q-GOL GOL-FD-SIM	S-ATG GOL-QLS-SIM	S-ATG w/confirmation GOL-QNS-SIM
Required Volume (µl)	20	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	18,75
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

INFLIXIMAB SHIKARI®

Q-INFLIXI • QS-INFLIXI • Q-ATI • Q-ATI w/confirmation • Q-ATI (Free/Total Ab)


INFLIXIMAB (Remicade®) ELISA

Infliximab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. Infliximab binds with high affinity to soluble and transmembrane forms of TNF- α to disrupt the proinflammatory cascade signaling. Binding of antibodies to TNF- α prevents TNF- α from interacting with its receptors and helps the patient recover. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.


SHIKARI® Q-INFLIXI: Enzyme immunoassay for the quantitative determination of Infliximab (Remicade®) in serum and plasma. This kit has been especially developed for the quantitative Infliximab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-INFLIXI: Infliximab ELISA has been especially developed for the specific and quantitative analysis of free infliximab in serum and plasma samples.

Shikari® (Q-INFLIXI) Infliximab ELISA



Shikari® (QS-INFLIXI) Infliximab ELISA



Catalog Number/Code	Q-INFLIXI INF-FD-REMI	QS-INFLIXI INF-SPEC-INF
Required Volume (µl)	10	10
Total Time (min)	70	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	0,003
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

INFLIXIMAB SHIKARI®

Q-INFLIXI • QS-INFLIXI • Q-ATI • Q-ATI w/confirmation • Q-ATI (Free/Total Ab)

INFLIXIMAB (Remicade®) ELISA


Demonstration of anti-infliximab antibodies during treatment with infliximab (Remicade®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Matriks Biotek® SHIKARI® Q-ATI Total/Free ADA ELISA Kit infliximabspecific antibodies that are free and bound infliximab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Remicade®.

SHIKARI® Q-ATI: Enzyme immunoassay for the qualitative determination of antibodies to Infliximab (Remicade®) in serum and plasma. This kit has been especially developed for the qualitative antibodies to Infliximab in serum and plasma samples.

SHIKARI® Q-ATI w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Infliximab (Remicade®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Infliximab in serum and plasma samples.

SHIKARI® Q-ATI (Free/Total Ab): Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to infliximab in serum and plasma.

Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation




Catalog Number/Code	Q-ATI INF-QLS-REMI	Q-ATI w/confirmation INF-QNS-REMI	Q-ATI (Free/Total Ab) INF-QNFT-REMI
Required Volume (µl)	20	20	40
Total Time (min)	140	140	95
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	+ / -	3,125	156
Spike Recovery (%)	-	Between 85 - 115	-
Shelf Life (year)	1	1	1
Assay Type	Qualitative	Quantitative	Semi Qualitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

INFLIXIMAB SHIKARI®

Q-INFLIXI • QS-INFLIXI • Q-ATI • Q-ATI w/confirmation • Q-ATI (Free/Total Ab)

INFLIXIMAB (Remicade®) ELISA

Infliximab through concentration (TC) measurement



INFLIXIMAB BIOSIMILAR SHIKARI®

Q-REMS • S-AIR • S-AIR w/confirmation • S-AIR (Free/Total Ab)

INFLIXIMAB BIOSIMILAR (Remsima®) ELISA


Infliximab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. Infliximab binds with high affinity to soluble and transmembrane forms of TNF- α to disrupt the proinflammatory cascade signaling. Binding of antibodies to TNF- α prevents TNF- α from interacting with its receptors and helps the patient recover. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

Remsima®, the world first biosimilar mAb (approved in 2013 by EMA). The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade®.

SHIKARI® Q-REMS: Enzyme immunoassay for the quantitative determination of free Infliximab-biosimilar (Remsima®) in serum and plasma. This kit has been especially developed for the quantitative determination of infliximab-biosimilar (Remsima®) in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-AIR: Enzyme immunoassay for the qualitative determination of antibodies to infliximab-biosimilar (Remsima®) in serum and plasma. This kit has been especially developed for the qualitative antibodies to infliximab-biosimilar (Remsima®) in serum and plasma samples.

Shikari® (Q-REMS) Infliximab Biosimilar ELISA



Catalog Number/Code	Q-REMS INF-FD-REMS	S-AIR INF-QLS-REMS
Required Volume (μl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

INFLIXIMAB BIOSIMILAR SHIKARI®

Q-REMS • S-AIR • S-AIR w/confirmation • S-AIR (Free/Total Ab)


INFLIXIMAB BIOSIMILAR (Remsima®) ELISA

SHIKARI® S-AIR w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Infliximab biosimilar (Remsima®) in serum and plasma with confirmation. SHIKARI® Quantitative Antibodies to Infliximab Biosimilar ELISA has been especially developed for the quantitative analysis of antibodies to infliximab biosimilar in serum and plasma samples. This kit is optimized with Remsima®.

SHIKARI® S-AIR (Free/Total Ab): Enzyme immunoassay for the semi-quantitative determination (screening) of total antibodies to infliximab biosimilar (Remsima®) in serum and plasma.

Demonstration of anti-infliximab antibodies during treatment with infliximab- biosimilar (Remsima®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Matriks Biotek® SHIKARI® S-AIRv3 ELISA Kit infliximab specific antibodies that are bound to infliximab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Remsima®.

Shikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation



Catalog Number/Code	S-AIR w/confirmation INF-QNS-REMS	S-AIR (Free/Total Ab) INF-QNFT-REMS
Required Volume (µl)	20	40
Total Time (min)	140	95
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	6,25	156
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Semi Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

IPILIMUMAB SHIKARI®

Q-IPI • S-ATI • S-ATI w/confirmation

IPILIMUMAB (Yervoy®) ELISA


Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab binds to CTLA-4 on the cell surface, effectively blocking the interaction between CTLA-4 and B7.1/B7.2. This leads to interruption of the negative signal mediated by CTLA-4, the resumption of signal 2, and a relative restoration of T-cell activation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-IPI: Enzyme immunoassay for the quantitative determination of specific Ipilimumab (Yervoy®) in human serum and plasma. This kit has been especially developed for the quantitative determination of ipilimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATI: Enzyme immunoassay for the qualitative determination of specific antibodies to Ipilimumab (Yervoy®) in human serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to ipilimumab in serum and plasma.

SHIKARI® S-ATI w/confirmation: Enzyme immunoassay for the quantitative determination of specific antibodies to Ipilimumab (Yervoy®) in human serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to ipilimumab in serum and plasma.

Shikari® (Q-IPI) Ipilimumab ELISA



Shikari® (S-ATI) Anti-Ipilimumab ELISA w/confirmation



Catalog Number/Code	Q-IPI IPI-FD-YER	S-ATI IPI-QLS-YER	S-ATI w/confirmation IPI-QNS-YER
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	6,25
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

IXEKIZUMAB SHIKARI®

Q-IXE • S-ATIXE


IXEKIZUMAB (Taltz®) ELISA

IXEKIZUMAB is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-IXE: Enzyme immunoassay for the quantitative determination of Ixekizumab (Taltz®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ixekizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATIXE: Enzyme immunoassay for the qualitative determination of specific antibodies to Ixekizumab (Taltz®) in human serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Ixekizumab in serum and plasma samples.

Shikari® (Q-IXE) Ixekizumab ELISA



Catalog Number/Code	Q-IXE IXE-FD-TAL	S-ATIXE IXE-QLS-TAL
Required Volume (µl)	5	20
Total Time (min)	105	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	3	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

NATALIZUMAB SHIKARI®

Q-NAT • S-ATNAT • S-ATNAT w/confirmation

NATALIZUMAB (Tysabri®) ELISA


Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-NAT: Enzyme immunoassay for the quantitative determination of specific Natalizumab (Tysabri®) in human serum and plasma. This kit has been especially developed for the quantitative determination of natalizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATNAT: Enzyme immunoassay for the qualitative determination of specific antibodies to Natalizumab (Tysabri®) in human serum and plasma. This kit has been especially developed for the qualitative determination of natalizumab in serum and plasma samples.

SHIKARI® S-ATNAT w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Natalizumab (Tysabri®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to natalizumab in serum and plasma samples.

Shikari® (Q-NAT) Natalizumab ELISA



Shikari® (S-ATNAT) Anti-Natalizumab ELISA w/confirmation



Catalog Number/Code	Q-NAT NAT-FD-TYS	S-ATNAT NAT-QLS-TYS	S-ATNAT w/confirmation NAT-QNS-TYS
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	1,87
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

NIVOLUMAB SHIKARI®

Q-NIVO • S-ATN • S-ATN w/confirmation

NIVOLUMAB (Opdivo®) ELISA


Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, and esophageal cancer. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-NIVO: Enzyme immunoassay for the quantitative determination of free Nivolumab (Opdivo®) in serum and plasma. This kit has been especially developed for the quantitative determination of Nivolumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATN: Enzyme immunoassay for the qualitative determination (screening) of antibodies to Nivolumab (Opdivo®) in serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to Nivolumab in serum and plasma samples.

SHIKARI® S-ATN w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Nivolumab (Opdivo®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Nivolumab in serum and plasma sample.

Shikari® (Q-NIVO) Nivolumab ELISA



Shikari® (S-ATN) Anti-Nivolumab ELISA w/confirmation



Catalog Number/Code	Q-NIVO NIV-FD-OPD	S-ATN NIV-QLS-OPD	S-ATN w/confirmation NIV-QNS-OPD
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	30	+ / -	20
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

OMALIZUMAB SHIKARI®

Q-OMA • S-ATO


OMALIZUMAB (Xolair®) ELISA

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) which treats the symptoms of asthma and chronic idiopathic urticaria by limiting the allergic response. It inhibits the binding of IgE to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Mast cell activation and the release of mediators, in response to allergen exposure and IgE, results in a cascade of events. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-OMA: Enzyme immunoassay for the quantitative determination of Omalizumab (Xolair®) in serum and plasma. This kit has been especially developed for the quantitative determination of Omalizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATO: Enzyme immunoassay for the qualitative determination of specific antibodies to Omalizumab (Xolair®) in human serum and plasma. This kit has been especially developed for the qualitative determination of Omalizumab in serum and plasma samples.

Shikari® (Q-OMA) Omalizumab ELISA



Catalog Number/Code	Q-OMA OMA-FD-XOL	S-ATO OMA-QLS-XOL
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

PALIVIZUMAB SHIKARI®

Q-PAL • S-ATPAL • S-ATPAL w/confirmation

PALIVIZUMAB (Synagis®) ELISA


Palivizumab is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-PAL: Enzyme immunoassay for the quantitative determination of Palivizumab (Synagis®) in serum and plasma. This kit has been especially developed for the quantitative determination of Palivizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATPAL: Enzyme immunoassay for the qualitative determination of specific antibodies to Palivizumab (Synagis®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Palivizumab in serum and plasma samples.

SHIKARI® S-ATPAL w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Palivizumab (Synagis®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Palivizumab in serum and plasma samples.

Shikari® (Q-PAL) Palivizumab ELISA



Shikari® (S-ATPAL) Anti-Palivizumab ELISA w/confirmation



Catalog Number/Code	Q-PAL PAL-FD-SYN	S-ATPAL PAL-QLS-SYN	S-ATPAL w/confirmation PAL-QNS-SYN
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	18,75
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

PEMBROLIZUMAB SHIKARI®

Q-PEM • S-ATP • S-ATP w/confirmation

PEMBROLIZUMAB (Keytruda®) ELISA


Pembrolizumab is a PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. As a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors, pembrolizumab binds with high affinity to the cell surface receptor programmed cell death protein 1 (PD-1) and antagonizes its interaction with its known ligands PD-L1 and PD-L2. The binding of pembrolizumab to PD-1 prevents this inhibitory pathway, causing a physiological shift towards immune reactivity and enhancing tumor immunosurveillance and anti-tumor immune response. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-PEM: Enzyme immunoassay for the quantitative determination of free Pembrolizumab (Keytruda®) in serum and plasma. This kit has been especially developed for the quantitative determination of Pembrolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATP: Enzyme immunoassay for the qualitative determination (screening) of antibodies to Pembrolizumab (Keytruda®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Pembrolizumab in serum and plasma samples.

SHIKARI® S-ATP w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Pembrolizumab (Keytruda®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Pembrolizumab in serum and plasma samples.

Shikari® (Q-PEM) Pembrolizumab ELISA



Shikari® (S-ATP) Anti-Pembrolizumab ELISA w/confirmation



Catalog Number/Code	Q-PEM PEM-FD-KEY	S-ATP PEM-QLS-KEY	S-ATP w/confirmation PEM-QNS-KEY
Required Volume (µl)	10	20	20
Total Time (min)	140	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	7,5
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

PERTUZUMAB SHIKARI®

Q-PER • S-ATPER


PERTUZUMAB (Perjeta®) ELISA

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two light chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2- positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-PER: Enzyme immunoassay for the quantitative determination of Pertuzumab (Perjeta®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Pertuzumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATPER: Enzyme immunoassay for the qualitative determination of specific antibodies to Pertuzumab (Perjeta®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Pertuzumab in serum and plasma samples.

Shikari® (Q-PER) Pertuzumab ELISA



Catalog Number/Code	Q-PER PER-FD-PER	S-ATPER PER-QLS-PER
Required Volume (µl)	5	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	30	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

RAMUCIRUMAB SHIKARI®

Q-RAM • S-ATRAM


RAMUCIRUMAB (Cyramza®) ELISA

Ramucirumab is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RAM: Enzyme immunoassay for the quantitative determination of specific Ramucirumab (Cyramza®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ramucirumab (Cyramza®) in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATRAM: Enzyme immunoassay for the qualitative determination of specific antibodies to Ramucirumab (Cyramza®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Ramucirumab in serum and plasma samples.

Shikari® (Q-RAM) Ramucirumab ELISA



Catalog Number/Code	Q-RAM RAM-FD-CYR	S-ATRAM RAM-QLS-CYR
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	5	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

RANIBIZUMAB SHIKARI®


Q-RAN

RANIBIZUMAB (Lucentis®) ELISA

Ranibizumab is a recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody directed against human VEGF-A.5 Ranibizumab binds to VEGF-A with high affinity as well as its biologically active forms, such as VEGF165, VEGF121, and VEGF110. Ranibizumab binds to the receptor-binding site of VEGF-A, preventing it from binding to its receptors - VEGFR1 and VEGFR2 - that are expressed on the surface of endothelial cells. Ranibizumab thereby attenuates endothelial cell proliferation, vascular leakage, and new blood vessel formation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RAN: Enzyme immunoassay for the quantitative determination of Ranibizumab (Lucentis®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ranibizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-RAN) Ranibizumab ELISA



Catalog Number/Code	Q-RAN RAN-FD-LUC
Required Volume (µl)	10
Total Time (min)	70
Sample	Aqueous Humour
Sample Number	96
Detection Limit (ng/ml)	0,625
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

RISANKIZUMAB SHIKARI®

Q-RIS • S-ATRIS • S-ATRIS w/confirmation

RISANKIZUMAB (Skyrizi®) ELISA


Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). As an interleukin-23 antagonist, Risankizumab used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease in adults. Risankizumab acts to prevent the release of pro-inflammatory cytokines and chemokines that often lead to inflammatory skin symptoms, such as redness, pain, and plaques. Risankizumab binds with a high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine, thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RIS: Enzyme immunoassay for the quantitative determination of free Risankizumab (Skyrizi®) in serum and plasma. This kit has been especially developed for the quantitative determination of Risankizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATRIS: Enzyme immunoassay for the qualitative determination of antibodies to Risankizumab (Skyrizi®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Risankizumab in serum and plasma.

SHIKARI® S-ATRIS w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Risankizumab (Skyrizi®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Risankizumab in serum and plasma.

Shikari® (Q-RIS) Risankizumab ELISA



Shikari® (S-ATRIS) Anti-Risankizumab ELISA w/confirmation



Catalog Number/Code	Q-RIS RIS-FD-SKY	S-ATRIS RIS-QLS-SKY	S-ATRIS w/confirmation RIS-QNS-SKY
Required Volume (µl)	5	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	6,25
Spike Recovery (%)	Between 85 - 115	-	-
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

RITUXIMAB SHIKARI®

Q-RITUX • S-ATR • S-ATR w/confirmation


RITUXIMAB (Rituxan®, Mabthera®) ELISA

Rituximab is a monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RITUX: Enzyme immunoassay for the quantitative determination of Rituximab (Rituxan®, Mabthera®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Rituximab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-RITUX) Rituximab ELISA



Catalog Number/Code	Q-RITUX RIT-FD-RM
Required Volume (µl)	10
Total Time (min)	135
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	3
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

RITUXIMAB SHIKARI®


Q-RITUX • S-ATR • S-ATR w/confirmation

RITUXIMAB (Rituxan®, Mabthera®) ELISA

SHIKARI® S-ATR: Enzyme immunoassay for the qualitative determination of specific antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Rituximab in serum and plasma samples.

SHIKARI® S-ATR w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Rituximab in serum and plasma samples.

Shikari® (S-ATR) Anti-Rituximab ELISA w/confirmation



Catalog Number/Code	S-ATR RIT-QLS-RM	S-ATR w/confirmation RIT-QNS-RM
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

SECUKINUMAB SHIKARI®

Q-SEC • S-ATSEC


SECUKINUMAB (Verxant®) ELISA

Secukinumab is an immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders. Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-SEC: Enzyme immunoassay for the quantitative determination of Secukinumab (Cosentyx® Verxant®) in serum and plasma. This kit has been especially developed for the quantitative determination of Secukinumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATSEC: Enzyme immunoassay for the qualitative determination of specific antibodies to Secukinumab (Cosentyx® Verxant®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Secukinumab in serum and plasma samples.

Shikari® (Q-SEC) Secukinumab ELISA



Catalog Number/Code	Q-SEC SEC-FD-VER	S-ATSEC SEC-QLS-VER
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	3	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

TOCILIZUMAB SHIKARI®

Q-TOC • S-ATOC • S-ATOC w/confirmation

TOCILIZUMAB (Actemra®) ELISA


Tocilizumab is an interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-TOC: Enzyme immunoassay for the quantitative determination of Tocilizumab (Actemra®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Tocilizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATOC: Enzyme immunoassay for the qualitative determination of Tocilizumab (Actemra®) in human serum and plasma. This kit has been especially developed for the qualitative determination of Tocilizumab in serum and plasma samples.

SHIKARI® S-ATOC w/confirmation: Enzyme immunoassay for the quantitative determination of Tocilizumab (Actemra®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Tocilizumab in serum and plasma samples.

Shikari® (Q-TOC) Tocilizumab ELISA



Shikari® (S-ATOC) Anti-Tocilizumab ELISA w/confirmation



Catalog Number/Code	Q-TOC TOC-FD-ACT	S-ATOC TOC-QLS-ACT	S-ATOC w/confirmation TOC-QNS-ACT
Required Volume (µl)	10	20	10
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	5
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

TRASTUZUMAB SHIKARI®

Q-TRAS • S-ATT • S-ATT w/confirmation

TRASTUZUMAB (Herclon®, Herceptin®) ELISA


Trastuzumab is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay ($K_d = 5$ nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-TRAS: Enzyme immunoassay for the quantitative determination of Trastuzumab (Herceptin®, Herclon®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Trastuzumab in serum and plasma samples between the Cmin and Cmax range of concentrations.


SHIKARI® S-ATT: Enzyme immunoassay for the qualitative determination of specific antibodies to Trastuzumab (Herceptin®, Herclon®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Trastuzumab in serum and plasma samples.

SHIKARI® S-ATT w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Trastuzumab (Herceptin®, Herclon®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Trastuzumab in serum and plasma samples.

Shikari® (Q-TRAS) Trastuzumab ELISA



Shikari® (S-ATT) Anti-Trastuzumab ELISA w/confirmation



Catalog Number/Code	Q-TRAS TRA-FD-HH	S-ATT TRA-QLS-HH	S-ATT w/confirmation TRA-QNS-HH
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	7,5
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

USTEKINUMAB SHIKARI®

Q-UST • QS-UST • S-ATU • S-ATU w/confirmation


USTEKINUMAB (Stelara®) ELISA

Ustekinumab is a targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.


SHIKARI® Q-UST: Enzyme immunoassay for the quantitative determination of Ustekinumab (Stelara®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ustekinumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-USTEKINUMAB: Ustekinumab ELISA has been especially developed for the specific and quantitative analysis of free Ustekinumab in serum and plasma samples.

Shikari® (Q-UST) Ustekinumab ELISA



Shikari® (QS-UST) Ustekinumab ELISA



Catalog Number/Code	Q-UST UST-FD-STE	QS-UST UST-SPEC-UST
Required Volume (µl)	10	10
Total Time (min)	70	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	2,5	2,34
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

USTEKINUMAB SHIKARI®


Q-UST • QS-UST • S-ATU • S-ATU w/confirmation

USTEKINUMAB (Stelara®) ELISA

SHIKARI® S-ATU: Enzyme immunoassay for the qualitative determination of antibodies to Ustekinumab (Stelara®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Ustekinumab in serum and plasma samples.

SHIKARI® S-ATU w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Ustekinumab (Stelara®) in serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to Ustekinumab in serum and plasma samples.

Shikari® (S-ATU) Anti-Ustekinumab ELISA w/confirmation



Catalog Number/Code	S-ATU UST-QLS-STE	S-ATU w/confirmation UST-QNS-STE
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

VEDOLIZUMAB SHIKARI®

Q-VEDO • S-ATV • S-ATV w/confirmation


VEDOLIZUMAB (Entyvio®) ELISA

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators. Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte $\alpha 4\beta 7$ integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies.


SHIKARI® Q-VEDO: Enzyme immunoassay for the quantitative determination of Vedolizumab (Entyvio®) in serum and plasma. This kit has been especially developed for the quantitative determination of Vedolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-VEDO: Vedolizumab ELISA has been especially developed for the specific and quantitative analysis of free Vedolizumab in serum and plasma samples.

Shikari® (Q-VEDO) Vedolizumab ELISA



Shikari® (QS-VEDO) Vedolizumab ELISA



Catalog Number/Code	Q-VEDO VED-FD-ENT	QS-VEDO VED-SPEC-VED
Required Volume (µl)	10	10
Total Time (min)	100	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	1,56	1
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

VEDOLIZUMAB SHIKARI®


Q-VEDO • QS-VEDO • S-ATV • S-ATV w/confirmation

VEDOLIZUMAB (Entyvio®) ELISA

SHIKARI® S-ATV: Enzyme immunoassay for the qualitative determination of antibodies to Vedolizumab (Entyvio®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Vedolizumab in serum and plasma samples.

SHIKARI® S-ATV w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Vedolizumab (Entyvio®) in serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to Vedolizumab in serum and plasma samples.

Shikari® (S-ATV) Anti-Vedolizumab ELISA w/confirmation



Catalog Number/Code	S-ATV VED-QLS-ENT	S-ATV w/confirmation VED-QNS-ENT
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

	Product Code (including version number)	Description		Sample Type	Method
Shikari® (Q-ABA)	ABA-FD-ORE	Abatacept (Orencia®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAB)	ABA-QLS-ORE	Abatacept (Orencia®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAB)	ABA-QNS-ORE	Abatacept (Orencia®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ADA)	ADA-FD-HUM	Adalimumab (Humira®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-ADA)	ADA-SPEC-ADA	Adalimumab (Humira®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATA)	ADA-QLS-HUM	Adalimumab (Humira®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATA)	ADA-QNS-HUM	Adalimumab (Humira®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATA)	ADA-QNFT-HUM	Adalimumab (Humira®)	Antibody screening - Free/Total semiquantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AF)	AFL-FD-EYL	Aflibercept (Eylea®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AF) High Sensitive	AFL-FD-SENS-EYL	Aflibercept (Eylea®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAF)	AFL-QLS-EYL	Aflibercept (Eylea®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAF)	AFL-QNS-EYL	Aflibercept (Eylea®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATE)	ATE-FD-TEC	Atezolizumab (Tecentriq®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAT)	ATE-QLS-TEC	Atezolizumab (Tecentriq®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AVE)	AVE-FD-BAV	Avelumab (Bavencio®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAV)	AVE-QLS-BAV	Avelumab (Bavencio®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-BEVA)	BEV-FD-AA	Bevacizumab (Avastin®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATB)	BEV-QLS-AA	Bevacizumab (Avastin®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATB)	BEV-QNS-AA	Bevacizumab (Avastin®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-CAN)	CAN-FD-ILA	Canakinumab (Ilaris®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATCAN)	CAN-QLS-ILA	Canakinumab (Ilaris®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATCAN)	CAN-QNS-ILA	Canakinumab (Ilaris®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-CERT)	CER-FD-CIM	Certolizumab (Cimzia®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATCER)	CER-QNS-CIM	Certolizumab (Cimzia®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-CET)	CET-FD-ERB	Cetuximab (Erbix®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATC)	CET-QLS-ERB	Cetuximab (Erbix®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay

Shikari® (S-ATC)	CET-QNS-ERB	Cetuximab (Erbix®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-DAR)	DAR-FD-DAR	Daratumumab (Darzalex®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATDAR)	DAR-QLS-DAR	Daratumumab (Darzalex®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-DEN)	DEN-FD-PRO	Denosumab (Prolia®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATD)	DEN-QLS-PRO	Denosumab (Prolia®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATD)	DEN-QNS-PRO	Denosumab (Prolia®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-DUR)	DUR-FD-IMF	Durvalumab (Imfinzi®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATDUR)	DUR-QLS-IMF	Durvalumab (Imfinzi®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ECU)	ECU-FD-SOL	Eculizumab (Solaris®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATEC)	ECU-QLS-SOL	Eculizumab (Solaris®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATEC)	ECU-QNS-SOL	Eculizumab (Solaris®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ETA)	ETA-FD-ENB	Etanercept (Enbrel®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATE)	ETA-QLS-ENB	Etanercept (Enbrel®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-EVO)	EVO-FD-REP	Evolocumab (Repatha®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATEVO)	EVO-QLS-REP	Evolocumab (Repatha®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AFA)	FIL-QNS-FRA	Filgrastim	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-GOL)	GOL-FD-SIM	Golimumab (Simponi®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATG)	GOL-QLS-SIM	Golimumab (Simponi®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATG)	GOL-QNS-SIM	Golimumab (Simponi®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-INFLIXI)	INF-FD-REMI	Infliximab (Remicade®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-INFLIXI)	INF-SPEC-INF	Infliximab (Remicade®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATI)	INF-QLS-REMI	Infliximab (Remicade®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATI)	INF-QNS-REMI	Infliximab (Remicade®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATIDUO)	INF-QNFT-REMI	Infliximab (Remicade®)	Antibody screening - Free/Total semiquantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-REMS)	INF-FD-REMS	Infliximab (Remsima®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-AIR)	INF-QLS-REMS	Infliximab (Remsima®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-AIR)	INF-QNS-REMS	Infliximab (Remsima®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-AIR)	INF-QNFT-REMS	Infliximab (Remsima®)	Antibody screening - Total semiquantitative	Serum/Plasma	Enzyme Immunoassay

Shikari® (Q-IPI)	IPI-FD-YER	Ipilimumab (Yervoy®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATI)	IPI-QLS-YER	Ipilimumab (Yervoy®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATI)	IPI-QNS-YER	Ipilimumab (Yervoy®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-IXE)	IXE-FD-TAL	Ixekizumab (Taltz®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATIXE)	IXE-QLS-TAL	Ixekizumab (Taltz®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-NAT)	NAT-FD-TYS	Natalizumab (Tysabri®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATNAT)	NAT-QLS-TYS	Natalizumab (Tysabri®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATNAT)	NAT-QNS-TYS	Natalizumab (Tysabri®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-NIVO)	NIV-FD-OPD	Nivolumab (Opdivo®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATN)	NIV-QLS-OPD	Nivolumab (Opdivo®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATN)	NIV-QNS-OPD	Nivolumab (Opdivo®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-OMA)	OMA-FD-XOL	Omalizumab (Xolair®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATO)	OMA-QLS-XOL	Omalizumab (Xolair®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-PAL)	PAL-FD-SYN	Palivizumab (Synagis®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATPAL)	PAL-QLS-SYN	Palivizumab (Synagis®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATPAL)	PAL-QNS-SYN	Palivizumab (Synagis®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-PEM)	PEM-FD-KEY	Pembrolizumab (Keytruda®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATP)	PEM-QLS-KEY	Pembrolizumab (Keytruda®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATP)	PEM-QNS-KEY	Pembrolizumab (Keytruda®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-PER)	PER-FD-PER	Pertuzumab (Perjeta®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATPER)	PER-QLS-PER	Pertuzumab (Perjeta®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-RAM)	RAM-FD-CYR	Ramucirumab (Cyramza®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATRAM)	RAM-QLS-CYR	Ramucirumab (Cyramza®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-RAN)	RAN-FD-LUC	Ranibizumab (Lucentis®)	Free drug	Aqueous Humour	Enzyme Immunoassay
Shikari® (Q-RIS)	RIS-FD-SKY	Risankizumab (Skyrizi®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATRIS)	RIS-QLS-SKY	Risankizumab (Skyrizi®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATRIS)	RIS-QNS-SKY	Risankizumab (Skyrizi®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay

Shikari® (Q-RITUX)	RIT-FD-RM	Rituximab (Rituxan®, Mabthera®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATR)	RIT-QLS-RM	Rituximab (Rituxan®, Mabthera®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATR)	RIT-QNS-RM	Rituximab (Rituxan®, Mabthera®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-SEC)	SEC-FD-VER	Secukinumab (Cosentyx®, Verxant®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATSEC)	SEC-QLS-VER	Secukinumab (Cosentyx®, Verxant®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-TOC)	TOC-FD-ACT	Tocilizumab (Actemra®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATOC)	TOC-QLS-ACT	Tocilizumab (Actemra®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATOC)	TOC-QNS-ACT	Tocilizumab (Actemra®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-TRAS)	TRA-FD-HH	Trastuzumab (Herceptin®, Herclon®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATT)	TRA-QLS-HH	Trastuzumab (Herceptin®, Herclon®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATT)	TRA-QNS-HH	Trastuzumab (Herceptin®, Herclon®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-UST)	UST-FD-STE	Ustekinumab (Stelara®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-UST)	UST-SPEC-UST	Ustekinumab (Stelara®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATU)	UST-QLS-STE	Ustekinumab (Stelara®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATU)	UST-QNS-STE	Ustekinumab (Stelara®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-VEDO)	VED-FD-ENT	Vedolizumab (Entyvio®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS- VEDO)	VED-SPEC-VED	Vedolizumab (Entyvio®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATV)	VED-QLS-ENT	Vedolizumab (Entyvio®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATV)	VED-QNS-ENT	Vedolizumab (Entyvio®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay

MATRIKS BIOTEK

20 years experience

innovation for health & wellness



You can order directly from us.
For detailed information and distribution, please check out
www.matriksbiotek.com



+90 (312) 485 42 94
+90 (546) 485 42 94

info@matriksbiotek.com
order@matriksbiotek.com


Gazi Uni. Teknoplaza C Blok No: 10/50c-47 Golbasi Ankara - Turkiye

LinkedIn

<https://tr.linkedin.com/company/matriks-biotechnology-co->



REFERENCES



REFERENCES



PUBLICATIONS	INSTITUTES	PRODUCTS
Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." <i>Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria</i> 46.1 (2021): 21-26.	Pharmacy Unit, Severo Ochoa University Hospital, Madrid, Spain	CET-FD-ERB
Güven, Deniz Can, et al. "Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy." <i>International Journal of Cancer</i> (2022).	Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.	COR-QNS-IGG-SRBD
Liu, Zheng, et al. "Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children." <i>Journal of Crohn's and Colitis</i> (2022).	Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Hunter Medical Research Institute, Kookaburra Circuit, Australia.	INF-FD-REMI ADA-FD-HUM
Kita, Toshihiro, et al. "Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial." <i>Journal of Gastroenterology and Hepatology</i> (2022).	Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki	INF-FD-REMI ADA-FD-HUM
Iwasaki, Takeshi, et al. "Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis." <i>Frontiers in immunology</i> 13 (2022).	Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.	INF-FD-REMI ADA-FD-HUM ETA-FD-ENB INF-QNS-REMI ADA-QNS-HUM ETA-QLS-ENB
Cantarelli, Lorenzo, et al. "Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease." <i>Medicina Clínica</i> (2022).	Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, Tenerife, Spain.	INF-FD-REMI
Kawamoto, Ami, et al. "Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis." <i>Inflammatory Bowel Diseases</i> 28.8 (2022): 1298-1299.	Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.	INF-FD-REMI
Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome, but carries high risk of adverse effects." <i>Nephrology Dialysis Transplantation</i> (2022).	Division of Nephrology and ICMR Center for Advanced Research in Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.	RIT-FD-RM
Chen, Yewei, et al. "Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome." <i>Frontiers in Pharmacology</i> (2021): 2348.	Department of Pharmacy, Children's Hospital of Fudan University, Shanghai, China	RIT-FD-RM
Linares, Raquel, et al. "Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn's disease." <i>Biomedicine & Pharmacotherapy</i> 147 (2022): 112653.	Hepatic and Intestinal Immunobiology Group, Departamento Medicina Clínica, Universidad Miguel Hernandez, Spain	ADA-FD-HUM
Kim, Eun Sil, et al. "Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients." <i>Gut and Liver</i> 16.1 (2022): 71.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	ADA-FD-HUM
Orts, Beatriz, et al. "Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease." <i>Frontiers in pharmacology</i> 12 (2021): 795272-795272.	Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain	ADA-FD-HUM INF-FD-REMI ADA-QNS-HUM INF-QNS-HUM
Pękala, Anna, and Rafał Filip. "Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis—A Prospective Polish Population Study." <i>Journal of Clinical Medicine</i> 10.22 (2021): 5311.	Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Rzeszow, Poland	INF-FD-REMS
MOHSEN, ENAS RIYADH, and NAAEL H. ALI. "IMPACT OF TH17/TREGFOXP3 CELLS RATIO ON RHEUMATOID ARTHRITIS PATIENTS RECEIVING ANTI TNF-THERAPY-." <i>Journal of Duhok University</i> 24.2 (2021): 90-102.APA	College of Medicine, University of Basrah-Iraq	ETA-QLS-ENB INF-QLS-REMI
De Gregorio, Michael, et al. "Higher Anti-tumor Necrosis Factor- α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas." <i>Clinical Gastroenterology and Hepatology</i> (2021).	St Vincent's Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia	ADA-FD-HUM INF-FD-REMI/ REMS
Нуриахметова, Т. Ю., et al. "Особенности ответа на инфликсимаб пациентов с воспалительными заболеваниями кишечника и анкилозирующим спондилитом." <i>Русский медицинский журнал. Медицинское обозрение</i> 5.2 (2021): 64-70.	FSBEI HE Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia	INF-FD-REMI INF-QLS-REMI INF-QNS-REMI

Liu, Shu, et al. "Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science (2021).	State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	RIT-FD-RM
Patil, A., Upadhyaya, S., Dawar, R., Dadhaniya, N., Sood, I., Gupta, S. J., Handa, R. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment. International Journal of Rheumatic Diseases (2019)	Department of Rheumatology, Indraprastha Apollo Hospitals, Delhi, India	INF-FD-REMI INF-QLS-REMI
Yang Wu, et al., Management Decisions in Crohn's Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels, Crohn's & Colitis 360, Volume 3, Issue 3, (2021)	Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia	ADA-FD-HUM INF-FD-REMI ADA-QNS-HUM INF-QNS-REMI
Tae Jong Jeong, Eun Sil Kim et al. Discontinuation of Azathioprine Could Be Considered in Pediatric Patients with Crohn's Disease who Have Sustained Clinical and Deep Remission, Scientific Reports (2021)	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine	INF-FD-REMI
Pekala, Anna, and Rafał Filip. "Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study" Journal of Clinical Medicine (2021)	Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Rzeszow, Poland	ADA-FD-HUM INF-FD-REMS
Alañón Pardo, M. M., et al. "Monitorización farmacocinética de terapias biológicas en enfermedad inflamatoria intestinal." Revista de la OFIL 31.1 (2021): 49-57.	Hospital General La Mancha - Centro (Alcázar de San Juan). Ciudad Real, Spain	ADA-QLS-HUM INF-QLS-REMI ADA-QNS-HUM INF-QNS-REMI
Little, Robert D., et al. "De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months." Digestive Diseases and Sciences (2021): 1-4.	Department of Gastroenterology, Alfred Health and Monash University, Melbourne 3004, Australia	ADA-FD-HUM INF-FD-REMI
Kim, Mi Jin, et al. "Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease." Journal of Pediatric Gastroenterology and Nutrition 72.6 (2021): 870-876.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.	ADA-FD-HUM
Ward, Mark G., et al. "Comparison of Sb2-Infliximab with Originator-Infliximab in the Measurement of Serum Concentrations A Short Communication." Therapeutic Drug Monitoring (2021).	Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Victoria	INF-FD-REMI
Mocenigo, Marco, et al. "Rapid, Cost-Effective Peptide/ Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples." ACS sensors 5.10 (2020): 3109-3115.	Ullisse BioMed Labs, Area Science Park, SS 14, km 163.5, 34149 Trieste, Italy Molecular Genetics and Biotechnology PhD study programme, University of Nova Gorica, Vipavska 13, Nova Gorica, Slovenia	TRA-FD-HH
Judit Szántó, Kata, et al. "Advances in the optimisation of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-antagonists." Expert Opinion on Biological Therapy (2021).	Department of Medicine of Szeged, Szeged, Hungary.	ADA-FD-HUM INF-FD-REMI ADA-QNS-HUM INF-QNS-REM
Esatoglu, Sinem Nihal, et al. "Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study." Frontiers in Immunology 11 (2020): 3378.	Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey	INF-FD-REMI INF-QNS-REMI
Padrón, Ivette Mourani, et al. "Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer." Journal of Oncology Pharmacy Practice (2020): 1078155220953873.	Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.	TRA-QLS-HH
Luber, Raphael P., et al. "Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease." Journal of Gastroenterology and Hepatology (2020).	Department of Gastroenterology, Alfred Hospital, Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria	INF-FD-REMI INF-QNS-REMI
Formica, María Lina, et al. "Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody- Bevacizumab-and Triamcinolone acetone for combined therapy in neovascular ocular pathologies." Materials Science and Engineering: C 119 (2020): 111398.	Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000 Córdoba, Argentina.	BEV-FD-AA
Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology (2020).	Frontier Science Center for Synthetic Biology, Key Laboratory of Systems Bioengineering (MOE), Collaborative Innovation Centre of Chemical Science and Engineering (Tianjin), and School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, P. R. China	CET-FD-ERB

Yokoyama, Yoko, et al. "Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab." <i>Journal of Crohn's and Colitis</i> (2020).	Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.	INF-QNS-REMI
Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study." <i>Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria</i> 44.3 (2020): 81-86.	Plataforma de Oncología, Hospital Quironsalud Torrevieja. 03184 Torrevieja (Alicante), España.	NIV-FD-OPD
Seong, Gyeol, et al. "Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle." <i>Microorganisms</i> 8.6 (2020): 874.	Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea	INF-FD-REMI
Nieto, Juan C., et al. "Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy." <i>Leukemia</i> (2020): 1-6.	Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.	NIV-FD-OPD
Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." <i>Acta Pharmacologica Sinica</i> (2020): 1-7.	Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.	RIT-FD-RM
Choi, So Yoon, et al. "Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients." <i>Journal of Korean Medical Science</i> 35.16 (2020).	Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea	ADA-FD-HUM ADA-QLS-HUM
González García, Jonathan, et al. "Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients." <i>Annals of Pharmacotherapy</i> (2020): 1060028020902318.	Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, Spain.	TRA-FD-HH
de Redín, Inés Luis, et al. "In vivo efficacy of bevacizumab-loaded albumin in the treatment of colorectal cancer." <i>Drug Delivery and Translational Research</i> (2020): 1-11.	Department of Chemistry and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Pamplona, Spain.	BEV-FD-AA
Abe, Kazuki, et al. "Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion." <i>Analytical Methods</i> 12.1 (2020): 54-62.	Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan	NIV-FD-OPD
Zhang, Jinhua, et al. "Synthetic sRNA-based Engineering of Escherichia coli for Enhanced Production of Full-length Immunoglobulin G." <i>Biotechnology Journal</i> (2020): 1900363.	Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology Tianjin University, Tianjin 300350, P. R. China	CET-FD-ERB
Flanagan, E., et al. "Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD." <i>JOURNAL OF CROHNS & COLITIS</i> . Vol. 13. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2019.	St Vincent's Hospital, Gastroenterology, Melbourne, Australia	ADA-FD-HUM INF-FD-REMI
Puente-Massaguer, Eduard, et al. "A statistical approach to improve compound screening in cell culture media." <i>Engineering in Life Sciences</i> 19.4 (2019): 315-327.	Departament d'Enginyeria Química, Biològica i Ambiental, Campus Bellaterra, Cerdanyola del Vallès, Universitat Autònoma de Barcelona, Barcelona, Spain	TRA-FD-HH
Choi, So Yoon, Ben Kang, and Yon Ho Choe. "Serum Infliximab Cutoff Trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease." <i>Gut and liver</i> (2019).	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul	INF-FD-REMI
González-García, J., et al. "Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions." <i>Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</i> 43.2 (2019): 50-52.	Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Tenerife. Spain	TRA-FD-HH
Llabot, Juan M., et al. "In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)." <i>Journal of Drug Delivery Science and Technology</i> 52 (2019): 379-385.	UNITEFA - CONICET, Facultad de Ciencias Químicas (FCQ-UNC). Córdoba, Argentina	BEV-FD-AA
Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience." <i>DEVELOPMENTAL IMMUNOTHERAPY AND TUMOR IMMUNOBIOLOGY</i> (2019)	Plataforma de Oncología, Hospital Quironsalud Torrevieja. 03184 Torrevieja (Alicante), España.	NIV-FD-OPD

Zapater, Pedro, et al. "Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease." <i>Inflammatory bowel diseases</i> (2019).	Servicio de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain.	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-HUM
Vasudevan, Abhinav, et al. "Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease." <i>Digestive diseases and sciences</i> (2018): 1-10.	Department of Gastroenterology and Hepatology, Eastern Health, Box Hill Hospital, Australia	ADA-FD-HUM INF-FD-REMI
Kang, Ben, et al. "Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease." <i>Journal of Crohn's and Colitis</i> (2018).	Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, South Korea	INF-FD-REMI INF-QNS-REMI
Bálint, Anita, et al. "Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis-results from multicentre observational cohort." <i>Expert opinion on biological therapy just-accepted</i> (2018).	Department of Medicine , University of Szeged , Szeged , Hungary.	INF-FD-REMI INF-QNS-REMI
González García, Jonathan, et al. "Influence of anthropometric characteristics in patients with Her2-positive breast cancer on initial plasma concentrations of trastuzumab." <i>Annals of Pharmacotherapy</i> 51.11 (2017): 976-980.	Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife), La Laguna, Spain	TRA-FD-HH
Kang, Ben, et al. "Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study." <i>Inflammatory bowel diseases</i> 24.3 (2018): 607-616.	Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Republic of Korea	INF-FD-REMI
Duricova, Dana, et al. "Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation." <i>Inflammatory bowel diseases</i> (2018).	IBD Clinical and Research Center, ISCARE IVF, a.s., Prague, Czech Republic	INF-FD-REMI ADA-FD-HUM
Gregoritz, Manuel, et al. "Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry." <i>European Journal of Pharmaceutics and Biopharmaceutics</i> 127 (2018): 194-203.	Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany.	BEV-FD-AA
de Redín, Inés Luis, et al. "Human serum albumin nanoparticles for ocular delivery of bevacizumab." <i>International journal of pharmaceutics</i> 541.1-2 (2018): 214-223.	Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Spain	BEV-FD-AA
Pérez, Irene, et al. "Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels." <i>Therapeutic Advances in Gastroenterology</i> 11 (2018): 1756284818783613.	Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, Madrid, Spain	INF-FD-REMI INF-QLS-REMI
Bolia, Rishi, et al. "Secondary Loss of Response to Infliximab in Pediatric Crohn Disease: Does It Matter How and When We Start?." <i>Journal of pediatric gastroenterology and nutrition</i> 66.4 (2018): 637-640.	Department of Gastroenterology Royal Children's Hospital Melbourne Parkville, Australia	INF-FD-REMI
Kang, Ben, et al. "Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn's disease patients treated with combined immunosuppressive therapy." <i>Journal of Crohn's and Colitis</i> 12.6 (2018): 644-652.	Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea	INF-FD-REMI INF-QLS-REMI
Shirai, Shimpei, et al. "Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy." <i>Inflammatory bowel diseases</i> 24.5 (2018): 1082-1091.	Departments of Internal Medicine and Gastrointestinal Endoscopy, Faculty of Medicine, Saga University, Saga City, Saga, Japan.	ADA-FD-HUM
Iwamoto, Noriko, Akinobu Hamada, and Takashi Shimada. "Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis." <i>Analytical biochemistry</i> 540 (2018): 30-37.	Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kuwabara-cho, Nishino-kyo, Nakagyo-ku, Kyoto 604-8511, Japan	TRA-FD-HH
Sugita, Naoko, et al. "Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease." <i>Journal of gastroenterology and hepatology</i> 33.3 (2018): 631-637.	Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.	ADA-FD-HUM
M. Kolar et al., "Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab" <i>Gastroent Hepatol</i> (2018) 72(1): 20-26	IBD Clinical and Research Centre, Prague, Czech Republic	INF-FD-REMI

Jing Chen et. al., "Tailor-Making Fluorescent Hyaluronic Acid Microgels via Combining Microfluidics and Photoclick Chemistry for Sustained and Localized Delivery of Herceptin in Tumor." ACS Appl. Mater. Interfaces, (2018).	Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, People's Republic of China	TRA-FD-HH
Beswick, Lauren, et al. "Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study." Journal of Crohn's and Colitis 12.3 (2017): 289-297.	Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Australia	INF-FD-REMI
Piñero, Paula, et al. "IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA." Journal of Molecular Medicine 95.11 (2017): 1227-1236.	CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.	INF-FD-REMI ADA-FD-HUM
Štefan Raffáč et al., "Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect" Neuroendocrinology Letters Volume 38 Suppl. 1 (2017)	Department of laboratory medicine, Louis Pasteur University Hospital, Košice, Slovakia	INF-FD-REMI INF-QNS-REMI
Ward, M. G., et al. "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease." Alimentary pharmacology & therapeutics 45.8 (2017): 1135-1145.	Department of Gastroenterology, Alfred Hospital, Melbourne, Vic., Australia.	ADA-FD-HUM
Kevin H, et al, "Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies": Oncotarget, 2018, Vol. 9, (No. 17), pp: 13623-13636.	Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven - University of Leuven, Leuven B-3000, Belgium	TRA-FD-HH
Aomori, Tohru, et al. "Suppression of infliximab antibody levels by azathioprine in patients with rheumatoid arthritis." Die Pharmazie-An International Journal of Pharmaceutical Sciences 72.2 (2017): 95-97.	Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8521, Japan	INF-FD-REMI INF-QNS-REMI
Kaito Shibata, et al. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin. Journal of Pharmaceutical and Biomedical Analysis Volume 146, Pages 266-272, 30 November 2017	Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan	CET-FD-ERB
Johannes Gojo, Robert Sauermann, Ursula Knaack, Irene Slave, Andreas Peyrl, Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Drugs R D 17:469-474, 2017.	Department of Pediatrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria	BEV-FD-AA
Ohem J, Hradsky O, Zarubova K, Copova I, Bukovska P, Prusa R, Malickova K and Bronsky J. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors. Dig Dis. Aug 18, 2017.	Gastroenterology and Nutrition Unit, Department of Paediatrics, Prague, Czech Republic	INF-FD-REMI INF-QNS-REMI
Al-Karkhi MA, Al-Ani MM, Jassim NA, Mahdi BM, Association Between HLA-DRB1 alleles and development of antibodies to infliximab in Iraqi patients with rheumatoid arthritis, Basic Research Journals, 6(3): 30-35, 2017.	Department of Microbiology and Immunology, Baquba Teaching Hospital.	INF-QNS-REMI
Bálint A, Rutka M, Végh Z, et al. Frequency and Characteristics of Infusion Reactions during Biosimilar Infliximab Treatment in Inflammatory Bowel Diseases: results from Central European nationwide cohort, Expert Opinion on Drug Safety, 16(8):885-890, 2017.	First Department of Medicine, University of Szeged, Szeged, Hungary;	INF-FD-REMI INF-QLS-REMI
Lombardi S, Bernardoni C, Bertolucci D, et al. Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy. Journal of Autoimmunity and Cell Responses, 4(1), 2017.	SSD Clinical Analysis and Immunoallergology, Massa Carrara, Italy	ETA-FD-ENB
Gregoritz M, Messmann V, Abstiens K, Brandl FP, Göpferich AM, Controlled antibody release from degradable thermoresponsive hydrogels cross-linked by Diels-Alder chemistry, Biomacromolecules, Just Accepted Manuscript, 2017.	Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany	BEV-FD-AA
Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017.	The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA	ETA-FD-ENB
Kolar M, Duricova D, Bortlik M, et al., Infliximab Biosimilar (Remsima TM) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre, Digestive Disease, 35:91-100, 2017.	a IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic	INF-FD-REMI INF-QLS-REMI

Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF- α Drugs Differently Affect the TNF α -sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016	Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy	ETA-FD-ENB ETA-QLS-ENB INF-FD-REMI INF-QLS-REMI ADA-FD-HUM ADA-QLS-HUM
Julsgaard M, Christensen LA, Gibson PR, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. Jul;151(1):110-9, 2016.	Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus C, Denmark.	INF-FD-REMI ADA-FD-HUM
Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL, Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J Oncol Pharm Pract. Sep 23, 2016.	Pharmacy, Complejo Hospitalario Universitario de Canarias, San Cristo´bal de La Laguna, Santa Cruz de Tenerife, Spain	TRA-FD-HH
Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver, 2016.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul	INF-FD-REMI INF-QNS-REMI
Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science, 7 (1156), 2016.	School of Life Sciences, Sun Yat-sen University, Guangzhou, China	BEV-FD-AA
Kang B., et al., Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn's Disease Under Combined Immunosuppression: Escalation versus Early Treatment	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	INF-QNS-REMI
Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis Advance Access published, 2016.	Department of Medicine, University of Szeged, Szeged, Hungary	INF-FD-REMI INF-QLS-REMI
Gutiérrez A, Zapater P, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol.,111(4):529-40, 2016.	Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, Spain.	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-HUM
Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr.; 19(2): 116-122, 2016.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	INF-QLS-REMI
Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther., 3:155-166, 2016.	Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan	INF-FD-REMI
Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)- α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol.,43(9):1018-23, 2016.	IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic,	INF-FD-REMI ADA-FD-HUM
Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, 14(11) : 95-100, 2015.	Department of Microbiology & Immunology, College of medicine, University of Baghdad	INF-QLS-REMI
Bodini G., Edoardo G. Giannini, Edoardo V. Savarino, and Vincenzo Savarino. Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. Am J Gastroenterol., Vol.110, 2015.	Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy.	ADA-FD-HUM
Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. J Gastroenterol,50:758-768, 2015.	CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-REMI
Fujita T, Murata Y, Hemmi S, Kajiwar M, Yabuki M, et al. (2015) Persistent Complement Activation is Associated with Insulin Resistance and Chronic Inflammation in Overweight Patients with Type 2 Diabetes with Dyslipidemia. Int J Immunol Immunother 2:007, 2015.	Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Japan	Q-TNF- α
Malíckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015.	Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic.	INF-FD-REMI

Lee Y.M. et al, Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPN 60: (737-743), 2015.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Goyang, South Korea	INF-QNS-REMI
Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015	Dept. of Microbiology & Immunology, college of medicine, University of Baghdad	INF-QLS-REMI
Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica, 667-678, 2015.	Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium	BEV-FD-AA
Aydın C, Ataoğlu H., Demonstration of β -1,2 Mannan Structures Expressed on the Cell Wall of <i>Candida albicans</i> Yeast Form But Not on the Hyphal Form by Using Monoclonal Antibodies Mikrobiyol Bul 49(1): 66-76, 2015.	Ankara Üniversitesi Biyoteknoloji Enstitüsü, Ankara, Türkiye	mAb-ACMK-1
Kozub P, Curkova AK, Zuzulova M, Simaljakova M, Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab, Clinical & Experimental Dermatology Research, 5(2), 2014.	Department of Dermatology and Venerology, Comenius University Faculty of Medicine, Bratislava, Slovakia,	INF-FD-REMI INF-QNS-REMI
Pallagi-Kunstár É. et al., Utility of serum TNF- α , infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014.	Department of Medicine, University of Szeged, H6720 Szeged, Hungary	INF-FD-REMI INF-QNS-REMI Q-TNF- α
Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, (478-489), 2014.	Department of Medicine at the University of Western Ontario in London, Ontario, Canada.	ADA-FD-HUM
Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology & Hepatology, 26:(485-487), 2014.	Gastroenterology Unit, Department of Internal Medicine V., University Hospital Bratislava, Bratislava, Slovakia.	INF-FD-REMI INF-QNS-REMI
Erdemli Ö, et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. 2014. Journal of Biomaterials Application, 29(4):524-42, 2014.	Department of Engineering Sciences, Middle East Technical University, Ankara, Turkey	ETA-FD-ENB
Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov A.A., Cherkasova M.V., Nasonov E.L. Efficacy Of Adalimumab In Early Rheumatoid Arthritis In Relation To Its Serum Level And The Presence Of Anti-Drug Antibody, Rheumatology Science and Practice, 52(6):624-630, 2014.	V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia	ADA-FD-HUM ADA-QLS-HUM
Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.	IBD Clinical and Research Centre, ISCARE, Charles University, Prague, Czech Republic	INF-FD-REMI AD-FD-HUM
Jung Y et al., "Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis", J. Control. Release 2013.	Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.	ETA-FD-ENB
Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease, Gut 0:1-9, 2013	Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, Spain	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-REMI
Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013.	Dept. of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark	INF-FD-REMI
Romero G., et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of Anti-TNF- α . Macromol. Biosci. 13: (903-912), 2013.	CIC biomaGUNE, Paseo Miramón 182 C, 20009 San Sebastian, Gipuzkoa, Spain.	ADA-FD-HUM
Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF- α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages **	Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan	ETA-FD-ENB
Bortlik M et al, "Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF- α therapy during pregnancy: three-center study", Scandinavian Journal of Gastroenterology. 48: 951-958, 2013.	IBD Clinical and Research Centre, ISCARE, Charles University, Prague, Czech Republic.	INF-FD-REMI AD-FD-HUM

Bodini G, Savarino V, Fazio V, et al. Relationship Between Drug Serum Concentration and Clinical Activity in Patients With Crohn Disease Who Achieved Remission With Adalimumab - a Prospective Study, <i>Aga, Volume 142, Issue 5, Supplement 1, Page S-388</i> , 2012.	Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.	ADA-FD-HUM ADA-QNS-HUM
Bortlik M, et al, Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease, <i>Journal of Crohn's and Colitis</i> , 2012.	IBD Clinical and Research Centre, ISCARE a.s., 1st Faculty of Medicine, Charles University in Prague, Czech Republic	INF-QNS-REMI
Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, <i>Autoimmun Highlights</i> , 2012.	Laboratory of Clinical Immunology and Allergology, Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Karlovo náměstí 32, 121 11 Prague 2, Czech Republic	INF-QNS-REMI
Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, <i>Journal of Dermatology</i> , 39: 1- 4, 2012.	Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan	AD-QLS-HUM INF-QLS-REMI
Seok Lee Y, et al, "Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up", <i>Pediatric Gastroenterology, Hepatology & Nutrition</i> , 15(4):243-249, 2012.	Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul	INF-QLS-REMI
Molnar T, et al, "Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease", <i>Z Gastroenterol</i> , 50 - A53, 2012.	First Department of Medicine, University of Szeged, Szeged, Hungary	INF-FD-REMI INF-QNS-REMI
Kato S, et al, "Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn's Disease Patient", <i>Crohn's & Colitis Foundation of America</i> , 2011.	Department of Gastroenterology and Hepatology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan	INF-QNS-REMI
Adisen E, et al, "Anti-infliximab antibody status and its relation to clinical response in psoriatic patients": A pilot study, <i>Journal of Dermatology</i> , 37: 708-713, 2010.	Department of Dermatology, Gazi University, Faculty of Medicine, Ankara, Turkey.	INF-QLS-REMI
Pekala, Anna, Rafał Filip, and David Aebisher. "Anti-drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: A prospective cohort study." <i>Journal of Clinical Medicine</i> 10.12 (2021): 2653.	Department of Gastroenterology, IBD Unit of Clinical Hospital, Rzeszow, Poland	INF-QNS-REMS
Hollevoet, Kevin, et al. "Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep." <i>Human Gene Therapy</i> 30.11 (2019): 1431-1443.	Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, University of Leuven, Belgium	TRA-FD-HH
Sakane, Hideo, et al. "Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13." <i>BMC rheumatology</i> 6.1 (2022): 1-5.	Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, 3-39-22, Showamachi, Maebashi, Gunma 371-8511, Japan	INF-QNS-REMI
Rentsch, Clarissa A., et al. "Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point Of Care Using Rapidly Assessed Drug Levels In Patients with Inflammatory Bowel Disease." <i>Therapeutic Drug Monitoring</i> (2022): 10-1097.	Department of Gastroenterology Alfred Health and Central Clinical School, Monash University. Melbourne, Australia	INF-FD-REMI
Golshani, Maryam, et al. "SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers." <i>Vaccines</i> 10.12 (2022): 2038.	Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic	COR-QNS-IGG-S1 COR-QNS-IGM-S1
Maspero, Marianna, et al. "S79 Long Term Outcomes of Straight Ileoanal Anastomoses Converted to Ileal Pouch Anal Anastomoses." <i>Official journal of the American College of Gastroenterology</i> ACG 117 (2022): S21.	Cleveland Clinic Foundation, Cleveland, Ohio, United States	INF-FD-REMI INF-QNS-REMI
Maffei Svobodová, Ludmila, et al. "Multidisciplinární spolupráce při výzkumu stanovení hladin protilátek IgG a IgM u onemocnění COVID 19." (2022).	Institute of Biophysics and Informatics, 1. Faculty of Medicine, Charles University, Prague, Czech	COR-QNS-IGG-SRBD COR-QNS-IGM-SRBD
POSTERS		
Choi, So Yoon, et al. "Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients." <i>Journal of Korean Medical Science</i> 35.17 (2020).	Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea	ADA-FD-HUM ADA-QLS-HUM
Little, R., et al. "P709 Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysis." <i>Journal of Crohn's and Colitis</i> 12.supplement_1 (2018): S469-S470.	Alfred Health and Monash University, Gastroenterology, Melbourne, Australia,	AD-FD-HUM

García Gil S, Ramos Díaz R., ANÁLISIS DE LA CONCENTRACIONES PLASMÁTICAS DE NIVOLUMAB EN EL TRATAMIENTO DEL CPNM	Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, La Laguna (Tenerife)	NIV-FD-OPD
H. Akbulut, M. Ocal et al., The trough levels of bevacizumab significantly affects the outcome of the treatment in patents with metastatic colorectal cancer: A Turkish Oncology Group Study	Medical Oncology, Ankara University School of Medicine, Ankara Oncology Hospital, School of Medicine. Ankara, TR	BEV-QNS-AA
Patil A, Upadhyaya SK, Dawar R, et al., Through Infliximab Levels and Anti-Infliximab Antibodies in Spondyloarthritis Patients on Treatment with Low Dose Infliximab: A Single Centre Cross-Sectional Study, BMJ Journals, Annals of the Rheumatic Diseases,(2017).	Rheumatology; Microbiology, Indraprastha Apollo Hospitals, Delhi, India	INF-FD-REMI INF-QNS-REMI
Malickova K, Duricova D , Kolar M, et al., No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results, First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, 2 ISCARE, IBD clinical and research centre, Prague, Czech Republic, (2017).	Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic.	INF-QLS-REMI
H. Akbulut, et al: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC). Annals of Oncology, Volume 27, 2016, 7-11 October 2016, Copenhagen, Denmark.	Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.	BEV-QNS-AA
Perez I, Fernandez L, Sanchez-Ramón S, P551 Comparison of 4 assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with inflammatory bowel disease,Hospital Clínico San Carlos, IBD Unit, Madrid, Spain, Hospital Clínico San Carlos, Clinical Immunology, IdiSSC, IBD Unit, Gastroenterology,2016 Madrid, Spain.	Hospital Clínico San Carlos, IBD Unit, Madrid, Spain	INF-FD-REMI
Goldberg R., et al, Predictors of sub-therapeutic infliximab oradalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions, ECCO 2014 Inflammatory Bowel Disease.	Monash University, Monash Health, Dept. of Gastroenterology, Melbourne, Australia	ADA-FD-HUM INF-FD-REMI
Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha therapy (ERA study):Infliximab and adalimumab cord blood levels correlate with maternal levels at birth, ECCO 2014 Inflammatory Bowel Disease.	Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark	ADA-QNS-HUM
Szepes Z., et al, Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis, ECCO 2014 Inflammatory Bowel Disease.	University of Szeged, First Department of Medicine, Szeged, Hungary	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-REMI
Julsgaard M, et al, Time since last drug exposure in pregnancy determines Adalimumab and Infliximab levels in neonates(Era Study), Italy 2014.	Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark	ADA-QNS-HUM
Bodini G, et al, Correlation between Adalimumab trough serum concentration, Anti-Adalimumab antibodies and TNF-Alpha levels with clinical outcome in patients affected by Crohn's disease,. United European Gastroenterology. Italy 2013.	Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy.	ADA-FD-HUM ADA-QLS-HUM
Duricova D, et al, Predictors of sustained response to infliximab with Crohn's disease: A single cohort study, Czech Republic	4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.	INF-FD-REMI
Lukas M, et al, Anti-infliximab antibodies in routine clinical practice is it worth to assess them, Czech Republic	PIGMOD Center, Laboratory of Cell Regeneration and Plasticity, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechev, Czech Republic.	INF-QLS-REMI
Malickova K, et al, Relationship between serum trough infliximab levels, serum antibodies to infliximab, serum albumin levels and clinical response to infliximab treatment in patients with inflammatory bowel diseases, Charles University in Prague Czech Republic. (2011)	Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University and General University Hospital, Prague, Czech Republic	IPI-QLS-YER
Malickova K, et al, Formation of antiphospholipid antibodies and antibodies to infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases, Charles University in Prague Czech Republic (2011).	Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Czech Republic	INF-FD-REMI INF-QNS-REMI
Malickova K, et al., Monitoring patients treated with infliximab: Assessing Anti-Infliximab antibodies, Czech Republic. EUROMEDLAB. Autoimmune diseases 2009. S115	Institute of Clinical Biochemistry and Laboratory Diagnostics, General Teaching Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic	INF-QLS-REMI

THESIS		
Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello Silvia Peña Caba	UNIVERSIDAD COMPLUTENSE DE MADRID, Madrid, Spain	CET-FD-ERB BEV-FD-AA
TNF- α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats Shin, Seung Han, M.D.	National University, Seoul, Korea	ETA-FD-ENB
A BIOLÓGIAI TERÁPIA HATÉKONYSÁGA ÉS KORLÁTAI KÜLÖNBÖZŐ TÍPUSÚ GYULLADÁSOS BÉLBETEGSÉGEKBEN Dr. Molnár Tamás	Szegedi Tudományegyetem	Q-TNF- α INF-FD-REMI INF-QNS-REMI
A PIKKELYSÖMÖR KLINIKAI, BIOKÉMIAI, IMMUNOLÓGIAI ÉS GENETIKAI JELLEGZETESSÉGEINEK VIZSGÁLATA Dr. Gyulai Rolland	Pécsi Tudományegyetem, ÁOK	Q-TNF- α INF-FD-REMI INF-QLS-REMI
La Spectrometrie De Masse Appliquee A La Quantification Absolue Des Anticorps Monoclonaux Therapeutiques En Milieu Plasmatique Pour La Realisation D'etudes Pharmacocinetiques Pharmacodynamiques Dr. Rachel LEGERON-LIEUTENANT	Université de Bordeaux, France	BEV-FD-AA
EVALUATION of TRANSSCLERAL PERMEABILITY EFFECTS of NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM in OCULAR DRUG APPLICATIONS Dr. NAGIHAN UĞURLU	Hacettepe University	BEV-FD-AA
INVESTIGATION OF THE PATHOMECHANISM OF DIARRHOEA-RELATED DISEASES Dr. ÉVA PALLAGI	University of Szeged	Q-TNF- α INF-FD-REMI INF-QNS-REMI
Radiomarcage y biodistribución mediante SPECT-CT de nanopartículas de seroalbúmina humana con bevacizumab Dr. ROCÍO RAMOS MEMBRIVE	Universidad de Navarra	BEV-FD-AA
ASOCIACIÓN ENTRE EL PERFIL DE CITOCINAS PRO-INFLAMATORIAS, LOS EVENTOS INMUNOGÉNICOS Y LA ACTIVIDAD CLÍNICA EN PACIENTES CON ARTRITIS REUMATOIDE TRATADOS CON INFliximab Y ADALIMUMAB Q.F.B. EMMANUEL ANTONIO ORTIZ SALDIVAR	UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS	AD-FD-HUM ADA-QLS-HUM
Nanoparticle and Macromolecular Transfer across the Human Placental Barrier, Michael Gruber MSc. BSc. Medical University of Graz, Department of Obstetrics and Gynaecology	Department of Obstetrics and Gynaecology, Medical University of Graz, Graz, Austria	TRA-FD-HH DEN-FD-PRO
CRUCIAL STEPS FOR TREATMENT OPTIMIZATION AND DECISION MAKING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT. Szántó, Kata Judit	Department of Medicine, Albert Szent-Györgyi Medical School University of Szeged Szeged, Hungary	ADA-FD-HUM INF-FD-REMI
PATENTS		
Imaging probe for angiogenic activity in pulmonary arterial hypertension Paul B. YuMarcelo DICARLI	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. MASSACHUSETTS, USA	BEV-FD-AA
CONTROLLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF- α Aysen TEZCANER Dilek Keskin Seza OZEN Bulent ATILLA Ali USANMAZ Cetin KOCAEFE Ozge ERDEMLI	ODTÜ MÜHENDİSLİK BİLİMLERİ BÖLÜMÜ, ANKARA	ETA-FD-ENB
The plant source recombinant humanized shellfish of a kind of optimization cuts down preparation method and the medical applications of monoclonal antibody,	CHINA	BEV-FD-AA
Genetically modified micro-organ secreting antibody and methods of use Reem MiariNir ShapirInbal ZAFIR-LAVIE	MEDGENETICS MEDICAL ISRAEL LTD., Misgav, Israel	TRA-FD-HH



www.matriksbiotek.com

MATRIKS
BIOTEK

20 *years experience*
innovation for health & wellness

